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Satellite cells are quiescent skeletal muscle specific stem cells that are activated in response to 
injury to aid in muscle repair and regeneration. The interaction of hepatocyte growth factor 
(HGF) with these cells is crucial for their activation. However, to date, research on the effect 
of HGF on skeletal muscle satellite cells has yielded conflicting data. Clarity is therefore 
required as to its effect on downstream myogenic processes. Furthermore, mouse and rat cell 
lines and primary culture have been widely used for in vitro studies to investigate the effect of 
HGF on skeletal muscle physiology and disease; very few studies have been carried out in 
primary cultured human skeletal myoblasts.  As a result, we aimed to investigate and 
compare the effect of HGF (2, 10 and 50 ng/ml) on mouse C2C12 myoblast versus primary 
culture human skeletal myoblast (HSkM) proliferation, migration and differentiation. 
Proliferation was assessed via both cell counts and crystal violet assay, while migration was 
investigated using the scratch assay. Differentiation was determined via analysis of expression 
patterns of transcription factors implicated in myogenic commitment (i.e. Pax7, MyoD) as 
well  expression of the structural protein Myosin Heavy Chain (MyHC). We demonstrate a 
dose-dependent effect of HGF on myoblast proliferation whereby an increase in proliferation 
was detected in response to 2 ng/ml HGF, whilst 10 ng/ml HGF resulted in a reduction in 
proliferation capacity of both C2C12 and HSkM myoblasts. Interestingly, the reduction in 
proliferation in response to 10 ng/ml HGF was accompanied by a down-regulation in Pax7 
expression during differentiation of both mouse and human myoblasts. HGF also affected 
myoblast migration and differentiation in a dose-dependent manner that was inversely 
proportional to proliferation. HGF (10 ng/ml) stimulated an increase in myogenic 
commitment and terminal differentiation of C2C12 and HSkM myoblasts as reflected by the 
increased percentage MyoD positive cells, improved fusion and greater MyHC expression. 
C2C12 myoblast migration was also stimulated at this HGF concentration, but reduced in 
response to the lower HGF (2 ng/ml) dose. The decrease in proliferation following incubation 
with 10 ng/ml HGF, allows cells to exit proliferation into either a mode of migration or 
differentiation. Our data confirms the importance of HGF during myogenesis and highlights 
the sensitivity of satellite cells to changing HGF concentration. This has implications in the 
regulation of skeletal muscle wound repair.  
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 LITERATURE REVIEW  
1.1 SKELETAL MUSCLE REGENERATION 
Skeletal muscle is the most abundant tissue of the body and is essential for locomotion, metabolism 
and production of heat (Anderson, 2006). It is composed of muscle fibres (termed myofiber)  and 
contractile units that are bound together by connective tissues (Baj et al., 2005). Most importantly, 
skeletal muscle has the ability to regenerate after injury or disease such as muscle dystrophy. The 
generation process of new muscle, called myogenesis, is facilitated by resident stem cells termed 
satellite cells (Tedesco et al., 2010) (Figure 1.1), which represent up to 12% of  nuclei in adult 
skeletal muscle (Baj et al., 2005). 
Satellite cells were discovered in 1961, between the basal lamina and sarcolemma of muscle fibres 
(Mauro, 1961). They have since emerged as a model of postnatal stem cells both in vivo and in vitro 
and are also of particular relevance in the treatment of inherited muscle diseases (Baj et al., 2005). 
Furthermore, they are not only involved in muscle regeneration, but also in myogenesis required for 
skeletal muscle growth, maintenance, and homeostasis (Boldrin et al., 2010). These cells are a 
source of committed, proliferative muscle precursors (termed myoblasts) in normal muscle and 
represent a reserve of cells for myogenesis and regeneration (Anderson, 2006).  
Satellite cells exist in a mitotically and a metabolically quiescent state and show limited 
transcription activity (Boldrin et al., 2010). When physiologically required (e.g. following injury, 
stress or growth), they become activated and enter into the cell cycle, proliferate and migrate to the 
site of injury (O'Reilly et al., 2008). These cells then differentiate and fuse with adjacent myofibers 
or form new fibers thereby participating in the regeneration process (Boldrin et al., 2010) (Figure 
1.1). The response of satellite cells is largely influenced by the nature of the injury (e.g. chemical, 
ischemic, and traumatic) (Baj et al., 2005), changes in the composition of the extracellular matrix 
(ECM) (Boldrin et al., 2010) and secretion of growth factors (Anderson, 2006).  
The ECM is a non-cellular structure that surrounds and supports all mammalian tissues and organs 
(Alberts et al., 2002). It provides vital physical scaffolding for the cells it surrounds and initiates 
biochemical and biomechanical signals that are required for tissue differentiation, morphogenesis 
and homeostasis. The ECM is also responsible for regulation of cell behaviour through (a) 




extracellular matrix signal transduction pathways (e.g. integrin signalling pathways) and (c) 
interaction with growth factors (e.g. HGF with heparin sulphate) (Bosman and Stamenkovic, 2003). 
Growth factors are essential for myogenesis and skeletal muscle regeneration. They play a crucial 
role in the activation of satellite cells from quiescence and also regulate myogenic processes such 
as proliferation, migration, differentiation and myotube fusion during skeletal muscle repair and 
regeneration. The growth factors which contribute the most to these processes are Fibroblast 
Growth factor (FGF), Transforming Growth Factor β (TGF-β), Insulin-like Growth Factor (IGF), 
Platelet Derived Growth factor (PDGF) and Hepatocyte Growth Factor (HGF) families (Gal-Levi et 















Figure 1.1: Schematic diagram of the processes involved in skeletal muscle regeneration after mild 
injury. When skeletal muscle is stressed or injured, satellite cells are activated from quiescence (A) and 
proliferate to generate precursors termed myoblasts (B). These myoblasts migrate to the site of injury (C), 
differentiate, align, and fuse to replace the injured fibre (D). Diagram compiled from the following 






1.1.1 Fibroblast Growth Factor (FGF) 
Fibroblast Growth Factor (FGF) refers to a large family of related polypeptide growth factors that 
comprise five members; FGF-1, 2, 5, 6 and 7 (Karalaki et al., 2009). FGF is secreted by fibroblasts 
and satellite cells and are released in high concentrations during inflammation after tissue 
disruption. FGF induce activation and proliferation of satellite cells to provide sufficient cells for 
regeneration. FGF also promote migration of distant satellite cells to site of injury (Husmann et al., 
1996) and inhibit differentiation through the negative regulation of MyoD and myogenin expression 
(Jones et al., 2005). FGF-1 and 2 stimulate satellite cell proliferation and inhibit differentiation. 
FGF-2 induces entry of satellite cells into the cell cycle, but does not accelerate the transition from 
proliferation to differentiation (Kastner et al., 2000). Expression of FGF-6 is stimulated after 
skeletal muscle injury and induces satellite cell morphological changes, alters their adhesion and 
ability to differentiate (Floss et al., 1997). FGF-7 regulates myoblast division and differentiation in 
developing myotubes and is expressed during embryonic limb muscle development (Husmann et 
al., 1996).  
The functions of FGF are mediated through binding to the FGF receptor (FGFR), a transmembrane 
tyrosine kinase receptor. Four distinct FGFR genes have been discovered, (FGFR 1-4) and of these 
FGFR1 and 4 are the most prominent in satellite cells (Floss et al., 1997) . The expression of these 
receptors is up-regulated during skeletal muscle repair and regeneration, however, FGFR-1 
regulates satellite cell proliferation whilst FGFR-4 regulates differentiation to aid in proper and 
effective repair (Kastner et al., 2000).  
 
1.1.2 Transforming growth factor-beta (TGF-β) 
Transforming growth factor-beta (TGF-β) is a member of a family of dimeric polypeptide growth 
factors and exists as three isoforms: TGF-β1, TGF-β2, and TGF-β3 (Droguett et al., 2006). TGF-β 
is secreted by nearly every cell in the body and regulates embryonic development as well as 
postnatal cell proliferation, migration, differentiation and wound healing (Husmann et al., 1996). 
Upon injury, TGF-β is released by platelets at the site of injury and it induces the production of 
more TGF-β by satellite cells; however, excessive production and deposition of TGF-β can lead to 
fibrosis (McLennan and Koishi, 2002). The common characteristic of all TGF-β isoforms is their 
ability to bind to and modulate the function of  ECM proteins such as biglycan (Liu et al., 2004). 




2009). TGF-β regulates ECM reorganization throughout muscle regeneration and is responsible for 
the reconstruction of basal lamina and ECM that surrounds the damaged myofibers and activated 
satellite cells (Husmann et al., 1996). 
 
1.1.3 Insulin-like growth factor (IGF) 
The insulin-like growth factor (IGF) comprises two isoforms, namely IGF-I and IGF-II (Karalaki et 
al., 2009, Philippou et al., 2007). IGF-I is known to induce skeletal muscle hypertrophy by 
increasing the size of myotubes, promoting DNA and protein synthesis as well as inhibiting protein 
degradation (Pelosi et al., 2007). During skeletal muscle regeneration, IGF-I promotes satellite cell 
proliferation by up-regulating the expression of intracellular mediators such as cyclin-D and is also 
able to stimulate differentiation by inducing myogenin gene expression (Bark et al., 1998).  
Moreover, IGF-I promotes satellite cell survival during early phases of differentiation. Following 
injury, IGF-I also modulates the inflammatory response by down-regulating pro-inflammatory 
cytokines and reducing fibrosis (Bark et al., 1998);(Hill and Goldspink, 2003).  
The role of IGF-II in skeletal muscle repair is not well defined; however, it has been shown to be 
involved in myotube formation (Philippou et al., 2007). Expression of IGF-I and II occurs at 
different stages of muscle regeneration, but IGF-I expression precedes that of IGF-II (Hayashi et 
al., 2004).  
 
1.1.4 Platelet derived growth factor (PDGF) 
Platelet derived growth factor (PDGF) was first identified in human platelets as a factor that 
promoted growth. PDGF has three isoforms: PDGF-AA, -AB and –BB. Following injury, PDGF-
BB is released from the injured myofibers, degranulating platelets and infiltrating activated 
macrophages; it stimulates satellite cell migration. It also enhances satellite cell proliferation, but 







1.1.5 Other factors in skeletal muscle regeneration 
In order to reach the site of injury during repair, myoblasts have to migrate through the extracellular 
matrix (ECM) (Boonen and Post, 2008). Matrix metalloproteinases (MMPs) play a pivotal role in 
the degradation of ECM components, which not only allows migration of the myoblasts, but also 
results in the release of and cellular exposure to cytokines (e.g. HGF, FGF) that regulate myoblast 
proliferation and differentiation (Torrente et al., 2000). MMP2 and 9 in particular, are secreted by 
satellite cells and their expression levels are increased during skeletal muscle injury and 
regeneration (Koskinen et al., 2002). They are secreted into the ECM as inactive precursors which 
are activated following cleavage by proteinases and plasmin (Torrente et al., 2000). When active 
they degrade basal lamina components (Brennan et al., 2004). 
The basal lamina is a specialized sheet of connective tissue that surrounds myofibers (Alberts et al., 
2002) (Figure 1.1). Integrity of the basal lamina is essential to keep the satellite cells in their niche; 
defects in the basal lamina allow the cells to move throughout the muscle leading to loss of the 
reserve population of these cells (Brennan et al., 2004). The most important constituents of the 
basal lamina are collagen IV, laminin 2 (LM-211) and proteoglycans such as decorin. Laminin and 
collagen IV form an intricate structure with multiple binding sites for proteoglycans and integrins 
(Boonen and Post, 2008). 
Integrins comprise a large family of cell surface receptors composed of an α- and β-subunit 
(Kovanen, 2002). After binding to the appropriate ligand, integrins act as signal transducers, 
inducing migration, cell shape change and cell-cell interactions (Brzoska et al., 2006). Integrin α7 is 
the main isoform located in skeletal muscle and it binds myofibers to laminin and is up-regulated 
during regeneration (Kaariainen et al., 2001). Integrin α3 is also located on quiescent satellite cells 
and is known to bind to laminin. The interaction of integrin α3 and laminin is essential for myoblast 
migration and differentiation during regeneration (Brzoska et al., 2006). 
Laminin refers to a family of large disulphide-linked heterotrimeric glycoproteins (400-900 kDa) 
that contain one α, β and γ subunit and are represent the major component of the basal lamina (Siler 
et al., 2000). The laminin trimers are characterized according to the composition of the α, β and γ 
chains and to date fifteen laminin isoforms have been identified. Of these isoforms, only laminin-2 
(LM-211) is specific for skeletal muscle (Gawlik and Durbeej, 2011). LM-211 consists of α2, β1 
and γ1 proteins (Ehrig et al., 1990). In addition, laminin-deficient mice completely lack the basal 




numbers decrease due to diminished proliferation rates and increased apoptosis. Absence of the 
laminin α2 chain results in muscular dystrophy in humans and mice (Boonen and Post, 2008). 
Collagens are important fibrous and structural proteins within the ECM and basal lamina. They 
constitute up to 30% of the total protein mass of a multicellular animal. Over time they form 
cumulative intermolecular cross-links leading to stiffness and reduced function in aged skeletal 
muscles (Avery and Bailey, 2005). Seven collagen isoforms have been identified, including 
collagen I, II, III, IV, V, VI and VII; which are all composed of three polypeptide α-chains coiled 
into a triple helix structure. However, only collagen IV is specific to the basal lamina of myofibers 
and is known to interact with laminin and several proteoglycans (Frantz et al., 2010).  
Proteoglycans are a family of glycoproteins located mainly in connective tissue and contain 
subunits of glycosaminoglycans. The proteoglycan family is composed of several proteins 
including decorin, hyaluronan and syndecans. These proteins occupy a part of the ECM within 
tissues and participate in the molecular events that regulate cell proliferation and adhesion. Decorin 
is known to be involved in myoblast differentiation and migration, in part by modulating the 
biological activities of growth factors such as TGF-β (Droguett et al., 2006). Hyaluronan is found in 
high concentrations on the myoblast cell surface and stimulates myogenesis by enhancing 
differentiation and influencing migration via its interaction with cell surface receptors such as  
CD44 (Mylona et al., 2006). Quiescent satellite cells express syndecan-3 and -4, which are 
transmembrane heparan sulphate proteoglycans that are up-regulated upon satellite cell activation. 
In syndecan-3 knockout mice, satellite cells express low levels of c-Met and contain an abnormally 
disorganized basal lamina. When muscle damage is induced in these animal models, scar tissue 
formation is prominent. In addition, isolated satellite cells differentiate abnormally, with fusion of 
the myoblasts into syncytia instead of myofibers (Cornelison et al., 2004);(Rauch et al., 2005). 
Skeletal muscle repair and regeneration is therefore regulated by numerous factors, one factor not 
yet discussed is hepatocyte growth factor (HGF), a key regulator of satellite cell activity during 
myogenesis and muscle regeneration (Cornelison et al., 2004). It is expressed not only in 
regenerating muscle, but also in uninjured muscle tissue; it is processed and  released upon injury, 
when it promotes the activation and proliferation of satellite cells for muscle repair (Cornelison and 
Wold, 1997, Bischoff, 1997). The ability of HGF to stimulate mitogenesis, morphogenesis, satellite 
cell migration and growth gives it a central role in skeletal muscle regeneration (Karalaki et al., 
2009).         




1.2 HEPTACTOCYTE GROWTH FACTOR (HGF) STRUCTURE AND FUNCTION 
Hepatocyte growth factor (HGF) was initially discovered in 1984 as an important agent that 
stimulated the growth of hepatocytes after rat liver damage (Michalopoulos et al., 1984); hence this 
factor was given the name hepatocyte growth factor (HGF). In 1989 it was isolated from human 
plasma (Zarnegar and Michalopoulos, 1989) and since then its role has been studied in various 
animals and tissues (Schmidt et al., 1995); (Gal-Levi et al., 1998a, Gal-Levi et al., 1998b); (Zeng et 
al., 2002). 
 
1.2.1 Structural and Biochemical Properties of HGF 
HGF, alternatively known as scatter factor, is a multidomain glycoprotein synthesized and secreted 
mainly by mesenchymal cells including fibroblasts, endothelial cells, vascular smooth muscle cells 
and satellite cells (Birchmeier and Gherardi, 1998). Upon synthesis, HGF is stored in the 
extracellular matrix (ECM) as a biologically inactive pro-HGF single-chain precursor 
(approximately 90kDa) (Grierson et al., 2000). However, in response to stimuli such as skeletal 
muscle injury,  pro-HGF is activated to a heterodimeric form via proteolytic cleavage by serine 
proteases at Arg494-Val495 (Tatsumi and Allen, 2004). In the activated form, HGF exists as a 
disulfide-linked heterodimer which contains an α (60kDa) and β-chain (30kDa). The α-chain, which 
is also the heavy chain, consists of an amino-terminal hairpin loop domain (HL) and four kringle 
domains (K1-K4); whilst the β-chain (light chain) consists of a serine protease homology (SPH) 
domain (Grierson et al., 2000) (Figure 1.2). Although HGF contains a SPH domain, it lacks any 
enzymatic (proteolytic) activity due to replacement of two of the three amino acids necessary for 
the catalytic triad (histidine and serine instead of glutamine and tyrosine, respectively) (Strain, 
1993) (Figure 1.2). 
The HL region of HGF contains clusters of amino acids that are necessary for sufficient binding of 
HGF to its receptor. The kringle domains (K1, K2, K3 and K4) play a pivotal role in the activation 
of the HGF receptor and are important for the mitogenic activity of HGF. The SPH domain 
contributes additional binding sites which are essential for efficient HGF receptor activation 


















Figure 1.2: HGF schematic structure. A) pro-HGF single chain precursor. B) HGF in its activated form. 
The four kringle domains (K) and HL domain are on the α-chain, and the SPH domain is on the β-chain. 
Proteolytic cleavage of pro-HGF into its active form is important for activity. Modified from (Grierson et al., 
2000). 
 
HGF is highly conserved across mammals. There is a 99% amino acid similarity between human 
and gorilla, and 91% between human and mouse. However, homology deviates in birds, with only 
75% amino acid similarity between human and chicken (Table 1.1). 
 
Table 1.1: HGF homology across different species 
Species Maximum amino acid identity 
Human Gorilla, Chimpanzee 99% 
Human Rhesus monkey 98% 
Human Hedgehog, Sheep, Rabbit 93% 
Human Guinea pig 91% 
Human Mouse 91% 
Human Rodents 88% 




Information retrieved from the Protein data base accessed on National Centre for Biotechnology Information 




1.2.2 Activators of HGF  
Activators of HGF include enzymes, which are either serine proteases of blood plasma origin or 
transmembrane serine proteases. Both classes are involved in HGF activation (Sisson et al., 2009).  
The proteases of blood plasma origin include urokinase-type plasminogen activator (uPA), tissue 
type plasminogen activator (tPA) and HGF activator (HGFA). Both uPA and tPA are known to 
function in blood clotting and ECM degradation, and are also known to activate HGF. These 
proteases are therefore ideal candidates for HGF-activating enzymes in injured tissues including 
skeletal muscle (Miyazawa, 2010). The HGF amino acid sequence is 40% similar to plasminogen (a 
proenzyme and substrate of uPA/tPA which facilitates the lysis of fibrin blood clots); uPA and tPA 
proteolytically cleave the single inactive HGF to its active heterodimeric form (Sisson et al., 2009). 
HGFA is located in the serum and plasma in an inactive or active form. The inactive precursor can 
be activated by thrombin via limited proteolysis in injured tissue. HGFA activation of HGF is more 
effective compared to uPA and tPA (Grierson et al., 2000). 
 Both matripase and hepsin are members of the family of type II transmembrane serine proteases 
(TTPS), which are known to activate pro-HGF (Kirchhofer et al., 2005) with comparable efficiency 
to that of HGFA (Miyazawa, 2010). These enzymes are localized on the cell surface in order to 
interact with HGF and other ECM components; they cleave pro-HGF at Arg thereby converting it 
to its active form (Kirchhofer et al., 2005) (Figure 1.2). 
 
1.2.3 Cellular regulation of HGF levels 
Regulation of HGF levels is essential as abnormal activation and overexpression of this cytokine 
leads to c-met gene amplification and mutations which result in the development of a variety of 
malignancies (Sattler et al., 2011). Regulation of HGF production and availability is very important 
and is attributed to several factors including two important HGFA inhibitors; HGFA inhibitor type 
1 (HAI-1) and type 2 (HAI-2) (both which are members of the Kunitz-type family of serine 
proteases) (Birchmeier and Gherardi, 1998). These competitive inhibitors are important 
physiological regulators of serine protease activity particularly hepsin and HGFA. In normal 
muscle, they bind to the active sites of the proteases thus preventing the interaction of HGF with its 
activators. However, during injury when HGF activation is essential, the inhibitors detach from the 




differentiation of myoblasts during muscle regeneration, HAI-1 and HAI-2 are up-regulated leading 
to down-regulation of active HGF (Shia et al., 2005).  
The expression of the HGF gene is restricted to mesenchymal cells including satellite cells and 
fibroblasts (Seki et al., 1991). HGF gene expression is up-regulated in response to tumor-necrosis 
factor (TNF-α), interleukins (IL-1α and IL-1β) and is down-regulated by growth factors such as 
transforming growth factor-β (TGF-β) (Shia et al., 2005).  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
1.2.4 HGF receptors: Structure and Function 
The HGF receptors exist in high and low affinity forms, namely c-Met and heparan sulphate 
proteoglycans (HSPGs), respectively. The α-chain of HGF heterodimer contains a high affinity 
receptor binding site for c-Met while the β-chain contains a low affinity receptor binding site for 
HSPGs (Basilico et al., 2008) (Figure 1.3). 
c-Met is a protooncogene product that is expressed as a transmembrane protein with tyrosine kinase 
activity in its cytoplasmic region (Grierson et al., 2000). This receptor is a 190 kDa glycoprotein, 
which can be cleaved into an α chain (50 kDa) and β chain (140 kDa). The α chain and a section of 
the β chain are linked by a disulfide bond and located on the cell surface, whilst the COOH terminal 
portion of β chain is located in the cytoplasm of the cell and contains the tyrosine kinase domain 
(Trusolino et al., 2010). The extracellular portion of c-Met consists of three domains: the 
semaphorin (Sema) domain that includes the whole of the α and part of the β chain; the plexin-
semaphorin-integrins (PSI) domain and four immunoglobulin-plexin transcription (IPT) domains 
(Basilico et al., 2008) (Figure 1.3). The Sema domain serves as a receptor recognition site, while 
the IPT domain is responsible for high affinity binding of c-Met to α-chain of HGF. The PSI 
domain functions as a link to orientate the extracellular portion of c-Met for effective and proper 
HGF binding (Kozlov et al., 2004). The cytoplasmic region is composed of three portions: a 
juxtamembrane sequence (down-regulates kinase activity upon phosphorylation); a catalytic region 
(responsible for activation of kinase activity following phosphorylation) and a carboxyl-terminal 
multifunctional docking site (important for downstream signalling) (Trusolino et al., 2010) (Figure 
1.3). The binding of HGF with the extracellular domains of c-Met (Figure 1.3) results in 
conformational changes within the domains. These conformational changes are a signal for 
autophosphorylation of the cytoplasmic domains and activation of downstream pathways such as 




al., 2000). HGF-c-Met binding is therefore important during embryogenesis and adult skeletal 




















Figure 1.3: Domain structure of HGF and c-Met. Both HGF and c-Met consist of α and β chains, which 
are used for binding of the two proteins during signal transduction. The c-Met extracellular portion is 
composed of three domains (Sema, the plexin-semaphorin-integrins (PSI) and immunoglobulin-plexin 
transcription (IPT)); the intracellular portion consists of a Juxtamembrane sequence, catalytic region and a 
multifunctional docking site in the C-terminal region. Diagram compiled from the following references: 






HSPGs are a family of cell surface proteoglycans which include syndecans and glypicans, located 
within the ECM (Dreyfuss et al., 2009). HSPGs function as scaffold structures that non-covalently 
bind and interact with a wide variety of growth factors including HGF and FGF. HSPGs are 
involved in cellular signalling either as receptors or co-receptors, they are known to be low affinity 
HGF co-receptors (Chirgadze et al., 1999). 
The ability of HSPGs to bind to HGF is facilitated by their low degree of sulphation;  their ligand-
binding sites are located within distinct sulphated domains formed by complex, cell-specific, 
chemical modifications of the heparan sulphate (HS) disaccharide repeat (Dreyfuss et al., 2009). 
Within the β-chain of HGF, the SPH domain is identified as a site important for HSPGs binding 
(Grierson et al., 2000) (Figure 1.3). Low affinity binding of HGF to HSPGs stimulates activation of 
phosphatidylinositol-3-kinase (PI3K) and mitogen-activated protein kinase (MAPK) pathways, 
signalling routes that regulate cell survival and proliferation, respectively (Derksen et al., 2002) 
(Figure 1.4). HSPGs promote dimerization of HGF, thereby stimulating c-Met activity and cross- 
linking to HGF. They also regulate HGF affinity for c-Met via induced conformational changes of 
HGF and protect HGF from proteolytic degradation (Birchmeier and Gherardi, 1998). 
Interestingly, it has been reported that HGF mediates colocalization of c-Met and HSPGs and the 
complex formed between HGF, c-Met and HSPGs bring essential intracellular signalling molecules 
such as adaptor proteins: growth factor receptor-bound protein 2 (Grb2) and Grb2-associated 
adaptor protein (Gab1) into proximity which facilitate c-Met activation (Derksen et al., 2002). 
HSPGs localize HGF to satellite cells and ECM components within the microenvironment and are 
also essential for the formation of a chemotactic gradient which is important for satellite cell 











1.2.5 HGF Signalling  
Co-operation between HGF and c-Met domains is essential for multifunctional biological activities 
of HGF (Basilico et al., 2008) (Figure 1.4).  Following HGF binding, c-Met is activated via 
receptor dimerization, internalized by clathrin-mediated endocytosis and recruited into early 
endosomes. c-Met then travels along the microtubule network to late intracellular compartments; 
this is followed by trans-phosphorylation of the catalytic domain and phosphorylation of the 
multifunctional docking site (Grierson et al., 2000) (Figure 1.3). The docking sites are essential for 
attachment of a variety of adaptor proteins and direct kinase substrates including the growth factor 
receptor-bound protein 2 (Grb2), Grb2-associated adaptor protein (Gab1), SRC homology protein 
tyrosine phosphatase 2 (Shp2), PI3K and signal transducer and activator of transcription 3 
(STAT3). This leads to the activation of downstream pathways which include mitogen-activated 
protein kinase (MAPK), PI3K/AKT and STAT3 that mediate c-Met-dependent satellite cell 
proliferation, migration, survival and differentiation (Birchmeier and Gherardi, 1998) (Figure 1.4). 
Ras (rat sarcoma viral oncogene homology) binds to Grb2 leading to indirect activation of Raf (v-
raf murine sarcoma viral oncogene homolog) kinases (Figure 1.4). This subsequently leads to 
activation of the MAPK cascade which results in successive activation of different protein kinases 
including extracellular signal-regulated kinases (Erk1 and Erk2) and p38. These downstream 
elements are responsible for activation of the cell cycle (leading to cell proliferation) and alterations 
in cytoskeletal functions that control cell migration (Grierson et al., 2000). Binding of Shp2 to 
Gab1 also results in the activation of the MAPK cascade and stimulation of satellite cell migration. 
Disruption of Shp2/Gab1 interaction has been reported to lead to defective myoblast migratory 
patterns (Li et al 2009). 
PI3K can bind either directly to c-Met or indirectly via Gab1, and signals through AKT to regulate 
cell survival and resistance to apoptosis via degradation of pro-apoptotic protein p53 (Birchmeier et 
al., 2003) (Figure 1.4). The direct binding of STAT3 to c-Met results in STAT3 phosphorylation, 
dimerization and translocation into the cell nuclei. This leads to regulation of genes implicated in 























Figure 1.4: HGF signalling in satellite cells. Phosphorylation of multifunctional docking sites results in 
recruitment of the adaptor proteins Grb2 and Gab1 as well as effector molecules PI3K and STAT3. PI3K can 
bind either directly to c-Met or indirectly via Gab1 which leads to the regulation of genes implicated in cell 
proliferation and differentiation. Activation of MAPK results in stimulation of cell proliferation, migration 
and inhibition of differentiation. HGF also promotes cell survival via PI3K signalling and can regulate cell 
proliferation and differentiation via STAT3 signalling. Diagram compiled from the following references: 









1.3 HGF BIOLOGICAL ACTIVITY 
HGF has been termed a pleiotrophic growth factor due to its ability to promote a wide range of 
biological activities in numerous target cells (Grierson et al., 2000); (Yamada et al., 2010b). Some 
of these biological and behavioural effects promoted by HGF in vitro and in vivo are listed in Table 
1.2 below.  
Table 1.2: Processes and cells targeted by HGF 
Process Target cells Reference 
Proliferation Satellite cells, keratinocytes, 
hepatocytes cells 
(Miller et al., 2000); (Moorby 
et al., 1995) 
Differentiation Satellite cells, mammary 
epithelial cells  
(Tatsumi et al., 2002); (Rosen 
et al., 1990) 
Cytoskeletal changes Satellite cells, hepatocyte cells (Ben-Ze'ev et al., 1990); 
(Pagan et al., 1997) 
Migration Satellite cells, MDCK cells (Grierson et al., 2000); 
(Stoker, 1989) 
Mitogenesis Satellite cells, hepatocyte cells, 
keratinocytes 
(Gal-Levi et al., 1998b); 
(Russell et al., 1984)  
Anti-apoptosis Myoblasts, bronchial and 
alveolar epithelial cells 
(Umeda et al., 2006) 
Activation Satellite cells (Gal-Levi et al., 1998b); 
(O'Reilly et al., 2008) 
(Yamada et al., 2010a)  








1.3.1 Role of HGF in skeletal muscle development during embryogenesis 
HGF and c-met genes are expressed throughout embryogenesis particularly during early 
organogenesis and gastrulation (Andermarcher et al., 1996). During early organogenesis, skeletal 
muscle develops from migratory and non-migratory muscle precursor cells that are produced by the 
lateral lip of the dermomyotome. Mice that lack c-Met and HGF die during the second part of 
gestation and lack migratory myogenic muscle precursor cells (Dietrich et al., 1999). During 
gastrulation, the expression of HGF and c-Met coincide; they are initially expressed in the 
endoderm and mesoderm and later in the node and notochord. During this phase, HGF regulates 
detachment of specific myogenic muscle precursor cells and subsequent migration from the somites 
into limb bud and diaphragm (Andermarcher et al., 1996); (van der Voort et al., 2000). The 
migration of these myoblasts is an important process in the development of skeletal muscle during 
embryogenesis and is therefore largely regulated by HGF. The absence of HGF and c-Met during 
embryogenesis prevents the development of limb muscle, shoulder muscle, and the diaphragm 
(Birchmeier and Gherardi, 1998); (Andermarcher et al., 1996). 
Interestingly, the c-met promoter contains a binding site for Pax3; in other words this transcription 
factor initiates gene expression of the HGF receptor (Epstein et al., 1996). Pax3 can therefore 
regulate the release of myoblasts by activating c-met genes during skeletal muscle development 














1.3.2 Role of HGF in satellite cell activation during adult skeletal muscle repair 
Satellite cell activation is central to skeletal muscle repair and is triggered primarily by HGF 
following skeletal muscle injury (Le Grand, 2007). Extrinsic mechanical stretch of the myofibers 
can trigger a number of intracellular signals, including nitric oxide synthesis that results in HGF 
activation. As previously discussed, HGF induces pro-myogenic mitogen activated protein kinase 
(MAPK) signalling cascades via c-Met (Karalaki et al., 2009). The p38α/β MAPK functions as a 
molecular switch to activate quiescent satellite cells (Jones et al., 2005). 
Satellite cell activation requires up-regulation of muscle transcription factors and muscle-specific 
genes (Karalaki et al., 2009). Quiescent satellite cells exhibit limited gene expression and protein 
synthesis (Le Grand, 2007). Paired and homeodomain box 7 gene (Pax7) is a member of a large 
family of transcription factors involved in cell determination during embryogenesis in mammals 
(Yablonka-Reuveni and Rivera, 1994). The Pax proteins are categorized by several conserved 
elements; two DNA binding domains, a paired domain and a homeodomain (Le Grand, 2007). Pax3 
is expressed by resident satellite cells in restricted muscle types, such as the diaphragm. Although 
both Pax3 and Pax7 are expressed during muscle development, Pax3 is the major transcription 
factor in embryonic muscle development, while Pax7 is essential in postnatal adult muscle 
(Yablonka-Reuveni et al., 2008). Pax7 is expressed by both quiescent and activated satellite cells 
and is also important for specification, survival and self-renewal of satellite cells and activation of 
myogenic genes (Le Grand, 2007). Studies by Gill et al., have demonstrated that expression of 
Pax7 during satellite cell activation and proliferation is largely regulated by HGF (Gill et al., 2010). 
Following activation, a portion of the satellite cell population will leave its niche and move to the 
injured site where it will increase the expression of Pax7, as well as myogenic regulatory factors 
(MRFs): myogenic differentiation factor (MyoD), myogenic factor 5 (Myf5) and MRF-4; whilst a 
portion of the population remains in the niche where they continually self-renew (Hawke and 
Garry, 2001). Quiescent satellite cells do not express MyoD, myogenin or myocyte enhancer factor 
2 (MEF2) or other known markers of terminal differentiation (Le Grand, 2007) (Figure 1.5). 
MRFs are involved in myogenic fate determination during early embryogenesis and adult skeletal 
muscle (Yablonka-Reuveni et al., 2008). When fully activated, satellite cells express MyoD. This 


























Figure 1.5: Role of HGF in satellite cell activation in adult skeletal muscle. Satellite cell activation, 
proliferation and differentiation is largely regulated by HGF (shown in green) and is based on the expression 
patterns of Pax7, MyoD, myogenin and MyHC. During proliferation, myoblasts co-express Pax7 and MyoD. 
Upon commitment to differentiation, the cells down-regulate Pax7 and express MyoD, myogenin and MyHC. 
Diagram complied from the following references: Karalaki et al., 2009; Le Grand, 2007; Yablonka-Reuveni 








1.3.3 Role of HGF during satellite cell proliferation during myogenesis 
Satellite cell proliferation is one of the key processes involved in myogenesis. Throughout 
embryogenesis, and in the adult skeletal muscle, the ability of satellite cells to proliferate is 
regulated by growth factors such as HGF and FGF (O'Reilly et al., 2008). During embryogenesis, 
cell proliferation is the primary means by which cell mass increases. Adult skeletal muscle 
generally express a variety of factors that act to maintain the proliferation status of satellite cells, 
these include transmembrane receptors (e.g. c-Met), intracellular signalling molecules and 
transcription factors (e.g. Pax7, MyoD (Figure 1.5)). However, in adult skeletal muscle 
proliferation becomes restricted as the capacity of the satellite cells to divide becomes exhausted as 
a result of progressive shortening of their telomere during each cell cycle (Zammit et al., 2006a).  
To date, in vitro studies of the role of HGF during satellite cell proliferation have yielded 
contradictory findings. Proliferation studies in C2C12 myoblasts have indicated promotion of cell 
growth by HGF (10 and 50 ng/ml) (Anastasi, 1997). These findings correlated with similar studies 
in rat skeletal myoblasts, where the rate of cell proliferation was shown to increase upon addition of 
HGF (3 and 30 ng/ml) (O'Blenes et al., 2010). In contrast, Yamada et al. demonstrated that high 
levels of HGF (over 10 ng/ml) suppress the proliferative activity of rat satellite cells (Yamada et al., 
2010a). Gal-Levi et al. came to similar conclusions using the chicken skeletal muscle cells and C2 
cells. They found a reduction in activation of quiescent satellite cells and decreased growth upon 













1.3.4 Role of HGF during satellite cell migration  
During early tissue formation, satellite cells proliferate and are capable of extensive migration 
(Andermarcher et al., 1996) (Figure 1.6). Migration of satellite cells occurs widely during both 
regeneration of skeletal muscle following injury and myogenesis for the purpose of muscle 
maintenance (Phillips et al., 1987). It has been reported that satellite cells migrate in the following 
ways: migration within a gradient of chemoattractants (e.g. in response to HGF, TGF-β) and 
migration of cells to injury site (during wound healing) (Firtel and Chung, 2000). 
Muscle trauma results in an increased release of HGF and FGF, that stimulate chemotaxis of 
satellite cells from surrounding niches (Watt et al., 1994). Focal crush injury at one end of a muscle 
results in the HGF-mediated activation and movement of satellite cells beneath the basal lamina 
from distant uninjured tissue toward the crush site (Bischoff, 1994). However, if the injury stimulus 
is perpendicular to the direction of the myofibers, some cells are able to cross the basal lamina of 
uninjured myofibers and migrate transversely through the muscle toward the injury site (Schultz et 
al., 1988). 
A migrating cell is usually polarized and exhibits cell projections such as filopodia (cylindrical, 
thin, needle-like projections protruding from the cell surface), lamellipodia (flat, broad, sheet-like 
structures at the leading edge of cells) at the front, and large focal adhesion complexes at the back 
(Figure 1.6). The typical Rho GTPases (Cdc42, Rac1 and RhoA), play a crucial role in controlling 
cell polarity and regulating different aspects of cytoskeletal dynamics. Cdc42 regulates the direction 
of migration, Rac induces membrane projection at the front of the cell through stimulation of actin 
polymerization and integrin adhesion complexes, and Rho promotes actin contraction in the cell 
body  (Mayor and Carmona-Fontaine, 2010) (Figure 1.6). Vinculin is a commonly expressed actin 
filament binding protein that localizes and concentrates in some sites of focal adhesions of cultured 
myoblasts (Le Clainche and Carlier, 2008). The focal adhesion sites and the role of vinculin in them 
are of particular interest for several reasons: focal adhesions are the main sites of cell adherence and 
they are located at the termini of stress fibres (Siegel et al., 2011). Vinculin expression levels have 
been shown to be higher in migrating cells, as it is mainly involved in the regulation of focal 
adhesions of migrating cells (Moon et al., 2004). 
Two main pathways that are implicated in cell migration in response to HGF are Ras/MAPK and 
PI3K. Activation of these pathways results in cytoskeletal reorganization which is essential for cell 
motility and the formation of focal adhesions. These changes in actin organizations in satellite cells 




2000) (Figure 1.6). Once activated to migrate, satellite cells can move into the injury site and repair 
the wound (Taher et al., 2002). 
Migration of satellite cells isolated from the rat hind leg muscle has been shown to be stimulated by 
HGF (1-50 ng/ml) and  inhibited at higher concentrations (100 ng/ml) (Bischoff, 1997). However, 
findings by Miller et al. in mouse skeletal muscle cells revealed that HGF increased cell migration 
at 6.25 ng/ml, but decreased in response to 50 ng/ml (Miller et al., 2000) (Table 1.3). Similarly, 
Suzuki et al., reported that exposure of C2C12 to exogenous HGF (15 ng/ml) increased migratory 















Figure 1.6: Mechanism of HGF-mediated satellite cell migration. HGF-c-Met binding results in 
autophosphorylation of c-Met leading to the activation of PI3K and MAPK which in turn regulate actin 
polymerization, filopodia and lamellopodia extension. A migrating cell needs to perform a coordinated series 
of steps to move starting with formation of filopodia, followed by lamellopodia extension and traction of the 
cells at the focal adhesion. Cdc42 regulates the direction of migration, Rac induces membrane projection at 
the front of the cell through stimulation of actin polymerization and integrin adhesion complexes, and Rho 
promotes actin contraction in the cell body. Diagram complied from the following references: Bischoff, 1994; 
Schultz et al., 1988; Mayor and Carmona-Fontaine, 2010; Warn et al., 1993. 




Following injury, skeletal muscle undergoes a process of degeneration and regeneration steps. 
These include proteolytic modifications of damaged myofibers and phagocytosis of debris by 
neutrophils, followed by necrotic changes during which damaged myofibers are removed by 
macrophages. Disruption of the basal lamina and plasma membrane releases HGF which then 
activates satellite cells to start proliferating and they ultimately differentiate into myotubes and 
myofibers. However, if the injury ruptures the basal lamina, fibroblasts migrate into the wound and 
deposition of collagen I occurs (fibrotic tissue); this prevents optimal muscle healing. It has been 
observed that TGF-β enhances the proliferation of fibroblasts and promotes formation of scar 
tissue, thereby impairing the healing process (Li et al., 2007; Shi and Garry, 2006). (See Section 
1.1.2) 
Similar to repair, regeneration requires the controlled up-regulation of MRFs (Myf5, myogenin, 
MyoD and myogenin) (Zammit et al., 2006b) (Figure 1.5). Myf5 is the earliest transcription factor 
to be expressed during myogenesis and is able to activate genes required for myogenic 
commitment.  MyoD is a key transcription factor for myogenic differentiation and is implicated in 
specification of myogenic lineage. Expression of myogenin marks the beginning of terminal 
myogenic differentiation together with a variety of regulatory and structural muscle genes of 
skeletal muscle myocytes (eg myosin heavy chain, MyHC). Myogenin expression results in down-
regulation of MyoD; and is also associated with fusion of myoblasts to new or existing myofibers 
leading to regeneration of the injured muscle (Le Grand, 2007).  
HGF has been shown to inhibit differentiation of myoblasts via the down-regulation of MyoD, 
MRF-4 and myogenin (Charge and Rudnicki, 2004); (Halevy et al., 2004); (Leshem et al., 2000); 
(Rosen et al., 1990). This inhibitory activity of HGF on differentiation is through regulation of p27 
and Twist protein. P27 is a cyclin-dependent kinase inhibitor, whereas Twist is an inhibitor of 
MyoD expression and therefore an inhibitor of the progression to terminal differentiation. When in 
the proliferative phase, satellite cell levels of p27 increase, but upon exit from cell cycle, cells 
down-regulate Twist expression and undergo differentiation. HGF induces Twist protein expression 
and down-regulates p27 levels; this supports the inhibitory effect of HGF on myogenic progenitor 






Exogenous administration of HGF (5 ng/ml) to turkey satellite cells and embryonic myoblasts 
inhibits their differentiation while exhibiting variation in its ability to stimulate proliferation (Zeng 
et al., 2002).  MyHC protein levels decrease when C2 satellite cells are exposed to increasing levels 
of HGF (0-50 ng/ml); suggesting an inhibition or delay in differentiation (Gal-Levi et al., 1998b). 
In addition, binding of HGF (50 ng/ml) to c-Met in vitro, has been shown to result in the silencing 
of MyoD and myogenin expression, inhibition of synthesis of MyHC as well as myotube formation 
of C2C12 myoblasts (Anastasi et al., 1997).  








Key:    indicates an increase in HGF effect and    indicates a decrease in HGF effect   
1.4 AIMS 
We have highlighted the role of HGF in regulating numerous key satellite cell functions. HGF has 
been shown to regulate proliferation, migration and differentiation of satellite cells during 
embryogenesis, wound repair and regeneration, but some results have been conflicting making it 
difficult to make overall deductions. 
A better understanding of the effects of HGF on myogenic processes (proliferation, migration and 
differentiation) could aid our understanding of the process of myogenesis. Thus the present study 
was designed with the following objectives: 
1. To investigate the role of different doses of exogenous HGF on proliferation, migration and 
differentiation of C2C12 mouse myoblasts versus primary cultured human skeletal myoblasts. 
 
2.  To utilize protein expression techniques to determine the molecular mechanisms underlying 





THE EFFECT OF HEPATOCYTE GROWTH FACTOR (HGF) ON C2C12 
MYOBLAST PROLIFERATION, MIGRATION AND DIFFERENTIATION 
ABSTRACT 
Satellite cells are mononucleated skeletal muscle specific cells that are located between the 
basal lamina and sarcolemma of myofibers. These cells are crucial for skeletal muscle 
regeneration in the event of injury or growth and their activation is largely regulated by 
HGF. To date, studies of the role of HGF during myogenesis have yielded conflicting and 
contradictory results making it difficult to make overall deductions. In this study, we 
investigated the effect of three different concentrations of HGF (2, 10 and 50 ng/ml) on C2C12 
myoblast proliferation, migration and differentiation. Cell counts were used to determine 





 expression was analysed, while terminal differentiation 
was assessed through total MyHC expression analysis. Vinculin localisation and expression 
was also examined to elucidate potential mechanisms underlying effects seen on proliferation 
and migration. Our results support widely documented in vitro evidence that HGF stimulates 
proliferation and regulates migration and differentiation. We show that treatment of C2C12 
cells with a low HGF concentration (2 ng/ml) promotes proliferation and decreases migration; 
under differentiation conditions, commitment to myogenesis and subsequent terminal 
differentiation were also decreased.  In contrast, treatment of C2C12 cells with a five-fold 
higher HGF concentration (10 ng/ml) promotes C2C12 migration (via down-regulation of 
vinculin) and differentiation but decreases proliferation. These findings indicate the 
importance of HGF in skeletal muscle regeneration and highlight the sensitivity of satellite 
cells to changing HGF levels. 
 








In response to skeletal muscle injury satellite cells are activated and enter the cell cycle. The 
activated satellite cells (termed myoblasts) undergo a series of proliferation steps (Halevy et al., 
2004), after which they withdraw from the cell cycle, align, differentiate and fuse into myofibers 
(Schmalbruch, 2006). The activation of satellite cells and subsequent expansion of the myoblast 
population is regulated by growth factors, such as fibroblast growth factor (FGF), insulin growth 
factor-1 (IGF-1) and hepatocyte growth factor (HGF) (Gal-Levi et al., 1998b); (O'Reilly et al., 
2008); (Yamada et al., 2010a); (Yamada et al., 2010b) (O'Blenes et al., 2010); (Miller et al., 2000). 
HGF is sequestered in the ECM of skeletal muscle and stored in an inactive form; however, upon 
injury it is released and consequently activates the satellite cell via receptor signalling mechanisms 
(Birchmeier and Gherardi, 1998). This growth factor has central roles in wound healing and tissue 
regeneration and regulates cell survival, motility and proliferation (Cornelison et al., 2004).  
The proliferation rate of satellite cells and any other cell types depends on: 1) the rate of cell 
division, 2) the portion of the cell population undergoing cell division, 3) regulation by  growth 
factors (Pardee, 1989). The production of HGF is elevated in muscle after damage, followed by a 
direct increase in satellite cell division and proliferation; suggesting a stimulatory effect of HGF on 
proliferation (O'Reilly et al., 2008). Some proliferation studies in C2C12 myoblasts indicated 
promotion of cell growth by HGF (at 10 and 50 ng/ml) (Anastasi, 1997). These findings correlated 
with similar studies in rat skeletal myoblast, where the rate of cell proliferation was shown to 
increase upon addition of HGF (at 3 and 30 ng/ml) (O'Blenes et al., 2010). In contrast, Yamada et 
al. demonstrated that high levels of HGF (over 10 ng/ml) suppress the proliferative activity of rat 
satellite cells (Yamada et al., 2010a). Gal-Levi et al. came to similar conclusions using the chicken 
skeletal muscle cells and C2 cells. They found a reduction in activation of quiescent satellite cells 
and a decrease in their growth upon exposure to exogenous HGF (20 and 50 ng/ml) (Gal-Levi et al., 
1998).  
Growth factor regulated changes in the actin cytoskeleton of satellite cells is essential for the 
maintenance of various cellular activities including proliferation and cytokinesis (Liu et al., 2008); 
(Khurana et al., 2002). One of the main cytoskeletal proteins with relevant implications is vinculin. 
Vinculin is a 117 kDa cytoskeletal adaptor protein located in the focal adhesions with central roles 
in cell contact regulation (Ezzell et al., 1997). Genetic inactivation of vinculin leads to paralysis and 
abnormalities in muscle structure and to embryonic lethality in mice (Marg et al., 2010). The 




adhesion assembly and prevention of actin polymerization (a necessary step in proliferation) (Ezzell 
et al., 1997). Furthermore, the changes in vinculin organization and expression in response to HGF 
is a necessary step in satellite cell progression through the cell cycle, suggesting a possible 
regulation of proliferation (Ben-Ze'ev et al., 1990). Studies performed on vinculin-null cells and 
animals indicate that besides modulating cell adhesion, this protein also affects some aspects of 
satellite cell migration (Siegel et al., 2011). 
Migration of satellite cells is a crucial step in skeletal muscle repair, regeneration and development 
(Ben-Ze'ev et al., 1990). Satellite cells in their migratory phase express high levels of vinculin (Le 
Clainche and Carlier, 2008) and upon exposure to HGF myoblasts show very rapid changes in 
morphology and cytoskeletal organization which is associated with changes in vinculin expression 
(Ben-Ze'ev et al., 1990). In rat muscle, exogenous HGF (10 ng/ml) resulted in increased migration 
and up-regulation of vinculin expression (Siegel et al., 2011); (Grierson et al., 2000). Vinculin 
influences the extension of lamellopodia during cell migration (Ezzell et al., 1997) and regulates 
satellite cell migration via ERK signalling pathway by controlling the accessibility of adaptor 
protein, paxillin for focal adhesion kinase (FAK) interaction (Subauste et al., 2004). 
The MAPK/ERK signalling pathway is one of the downstream pathways activated when HGF 
binds to c-Met and is known to regulate satellite cell migration (Grierson et al., 2000).  HGF is 
reported to act as a chemo-attractant of myoblasts and to increase their migration both in vitro and 
in vivo (Tatsumi et al., 2002); (Tatsumi and Allen, 2004). HGF null mutant mice completely lack 
muscle in the limb, supporting an important role of HGF in regulation of migration of precursor 
limb cells from the dermomyotome to their final location where they differentiate to form skeletal 
muscle (Bladt et al., 1995).  Migration of satellite cells isolated from the rat hind leg muscle is 
stimulated by HGF (1-10 ng/ml) and is inhibited at higher HGF concentrations (100 ng/ml) 
(Bischoff, 1997). Similar results have been produced by Miller et al. in mouse skeletal muscle cells 
where HGF increased cell migration at 6.25 ng/ml, but decreased it at 50 ng/ml (Miller et al., 2000). 
HGF stimulated (0.1, 1 and 6 ng/ml) C2C12 cell expression of MMP-9 has been reported to be 







Besides stimulating skeletal muscle precursor cell proliferation and migration, HGF is also 
implicated in regulating their differentiation during myogenesis (Li et al., 2008). Skeletal muscle 
differentiation is the final step of myogenesis regulated by several myogenic regulatory factors 
(MRFs) including MyoD, Myf-5, MRF-4 and myogenin. MRFs are proteins expressed in cells 
committed to differentiate and, together with Pax7, are implicated in specification of the myogenic 
lineage (McFarlane et al., 2008); (Buckingham et al., 2006); (Seale et al., 2004). Pax7 is expressed 
in quiescent satellite cells and is not only necessary for specification, but maintenance, survival and 
self-renewal of satellite cells (Kuang et al., 2006); (Seale et al., 2004); (Zammit et al., 2006b).  
Following activation and proliferation, satellite cells initially co-express Pax7 and MyoD 
(McFarlane et al., 2008), but subsequently down-regulate Pax7 in order to allow the induction of 
myogenin and Myosin Heavy Chain (MyHC) during terminal differentiation (Knapp et al., 2006).  
Accumulating evidence shows that HGF influences differentiation of myoblasts via the down-
regulation of MyoD, Myf-5, MRF-4 and myogenin (Charge and Rudnicki, 2004); (Halevy et al., 
2004); (Rosen et al., 1990). Leshem et al. showed that the inhibiting effects of HGF on 
differentiation is through co-ordinated regulation of p27 (a cyclin-dependent kinase) and Twist 
protein (a basic helix-loop-helix transcription factor) (Leshem et al., 2000). Exogenous 
administration of HGF (5 ng/ml) to turkey satellite cells and embryonic myoblasts inhibit their 
differentiation while exhibiting variation in its ability to stimulate proliferation (Zeng et al., 2002).  
MyHC protein levels decrease when satellite cells are exposed to increasing levels of HGF (0-50 
ng/ml); suggesting an inhibition or delay in differentiation (Gal-Levi et al., 1998b).   
Previous work on HGF has focused on proliferation in combination with either migration or 
differentiation; in our study we aimed to investigate the effect of HGF on all three processes 
(proliferation, migration and differentiation) in C2C12 myoblasts. According to the literature, a 
wide range of HGF doses (0.1-100 ng/ml) have been used in numerous cell lines, using various 
analysis methods, culture periods and culture protocols; inconsistencies were therefore reported. In 
this study, we investigated the effect of three different concentrations of HGF (2, 10 and 50 ng/ml) 
on proliferation, migration and differentiation. The effect of HGF on protein expression levels of 







2.2. EXPERIMENTAL PROCEDURE 
2.2.1. Cell culture 
Murine C2C12 cells were donated by the Cape Heart Centre (University of Cape Town). This 
immortalized cell line was originally derived from satellite cells from the thigh muscle of female 
mice and are adherent in culture. They can be maintained in an undifferentiated state if cultured and 
maintained in sub-confluent state in growth media; however, in differentiation media, they 
differentiate first into myocytes and after several days in media they form myotubes (Yaffe and 
Saxel, 1977). C2C12 cells have myogenic properties and were used for the experiments to analyse 
proliferation, migration and differentiation. Passages ranging from 11-20 were used.  
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Scientific 
Laboratories, USA, cat.SH30243.01) supplemented with 10% (v/v) fetal bovine serum (Biowest, 
USA, cat.S181H-500), 2% (v/v) L-glutamine (Lonza, USA, cat.BE17-605E) and 2% (v/v) 
Penicillin-Streptomycin (Lonza, USA, cat.DE17-602E). This growth media was used for both 
proliferation and migration assays. For differentiation studies, cells were cultured to 70-80% 
confluence then changed from growth media to DMEM supplemented with 2% (v/v) horse serum 
(Biowest, USA, cat.S090H-100). Human HGF (PeproTech, USA, cat.100-39) was used at a final 
concentration of 2, 10 and 50 ng/ml. C2C12 cells were incubated at 37
o
C in a humidified 
atmosphere at 5% CO2. All experiments were carried out under sterile conditions in a Class II 
Biohazard Safety Cabinet. 
 
2.2.2. Determination of C2C12 myoblast proliferation: 
 
2.2.2.1. Crystal violet assay 
Crystal violet assay was conducted as previously described by Gillies et al., (Gillies et al., 1986). 
Briefly, to analyse the effect of HGF on proliferation, a standard curve was first generated (see 
Appendix E) then 3 x 10
4
 cells/well were seeded in 6-well plates containing growth media and 
incubated at 37
o
C, 5% CO2 for 24 h. The media was changed to growth media containing 0, 2, 10, 
50 ng/ml HGF and cells were incubated for a further 24 h. Cells were then stained with crystal 
violet solution (Sigma, Germany, cat.C-3886) and absorbance determined at 595 nm using an 





2.2.2.2. Cell count assay 
Cells (5 x 10
4
) were seeded in T25 tissue culture flasks (Nunc, USA, cat.65232) containing growth 
media and incubated at 37
o
C, 5% CO2 for 24 h. HGF (0, 2, 10 and 50 ng/ml) was then added to the 
flasks and incubated for a further 24 h. Thereafter, cells were trypsinised for 5 min and a small 
sample (20 µl) was removed and transferred onto a Hemocytometer counting chamber where cells 
were carefully counted using a brightfield microscope (10 X magnification). 
 
2.2.3. Cell viability test 
Cells were plated at 3 x 10
4 
per T25 flask and incubated at 37
o
C, 5% CO2 for 24 h. The growth 
media was replaced with normal growth media, growth media containing HGF (10 ng/ml) or 
serum-free growth media (as a positive control) (Niesler et al., 2007), and cells incubated for a 
further 24 h. Cell were stained with trypan blue (Biorad, USA, cat.145-0013) and viability 
determined using an automated TC-20 cell counter (Bio-Rad, USA, serial.508BR1910).  
 
2.2.4. Migration: Scratch assay 
C2C12 myoblasts were plated at 5 x 10
4
 cells/well on coverslips in 24-well culture plates (Cell Star, 
USA, cat.66210) and allowed to reach 80% confluence. Cells were scratched as described 
previously (Goetsch and Niesler, 2011) using a sterile loading tip and fresh growth media 
containing 0, 2, 10 or 50 ng/ml HGF was added. The rate of wound closure was observed using the 
Olympus CKX41 brightfield microscope at 0, 3, 5 and 7 h and images were taken at the different 
time points with Motic 3 megapixel camera. The edges of the wound were traced using Motic 2.0 
image analysis software which measured the area of the wound.  Percentage wound closure was 
then calculated using the following equation: 
  ound closure   
Area of wound at 0 h  Area of wound x h 
Area of wound at 0 h







2.2.5. Immunocytochemistry (Proliferation and Migration) 
Proliferating and migrating cells were fixed in 4% paraformaldehyde for 15 min, blocked with 5% 
donkey serum (Biowest, USA, cat.S2170-100) for 30 min. Differentiating cells were fixed in 4% 
paraformaldehyde and permeabilized with 0.1% Triton X-100 (Sigma, Germany, cat.T9284) for 20 
min and blocked with 5% donkey serum for 30 min. Primary antibodies were added overnight and 
dilutions used were as follows: monoclonal mouse anti-vinculin antibody (Sigma, USA, cat.V9131; 
1:2000), monoclonal goat anti-Pax7 antibody (Santa Cruz, USA, cat.sc-7748; 1:100), rabbit 
polyclonal anti-MyoD (Santa Cruz, USA, cat.sc-760; 1:100), monoclonal mouse MF-20 
(Developmental Hybridoma Studies, USA, cat.M29; 1:100). DyLight 488-conjugated AffiniPure 
donkey anti-rabbit lgG (Jackson ImmunoResearch, USA, cat.CN-711-485-152), DyLight 549-
conjugated AffiniPure donkey anti-goat lgG (Jackson ImmunoResearch, USA, cat.CN-703-505-
003) and DyLight 594-conjugated AffiniPure donkey anti-mouse lgG secondary antibodies 
(Jackson ImmunoResearch, USA, cat.CN-715-515-151) were used at 1:1000 and incubated for 1 h. 
Hoechst nuclei stain (Sigma, Germany, cat.B2261; 10 µg/ml stock; 1:2000) was added to all the 
cells for 5 min. Moviol was used as the mounting agent. All images were captured using the Zeiss 
710LSM confocal microscope. 
 
2.2.6. Percentage MyoD and Pax7 expressing myoblasts and Differentiation index 
Five random fields of view of differentiated cells (> 30 cells/field of view) were captured using the 
Zeiss 710LSM confocal microscope and analysed with ImageJ software (http://rsbweb.nih.gov/ij/) 
or Zen 2009 software. The percentage MyoD and Pax7 expressing myoblasts, as well as the 
differentiation index were calculated using the following formulae:  
  MyoD  cells  
  umber of nuclei staining positive for MyoD
Total number of nuclei 
   100   
 
  Pax7  cells   
  umber of nuclei staining positive for Pax7
Total number of nuclei 
   100   
 
  Differentiation index   
  umber of MyHC positive cells (myocytes/myotubes) 
Total number of nuclei




2.2.7. Immunocytochemistry (Differentiation) 
Cells were differentiated for 5 days then fixed in 4% paraformaldehyde containing 0.1% Triton X-
100 (Sigma, Germany, cat.T9284) for 20 min, blocked with 5% donkey serum for 30 min. 
Phalloidin stain (Sigma, USA, cat.P1951; 1:16 000) was added for 45 min. Hoechst nuclei stain 
(Sigma, Germany, cat.B2261; 10 µg/ml stock; 1:2000) was added to all the cells for 5 min. Five 
random fields of view were captured using the Zeiss 710LSM confocal microscope. ImageJ 
software was utilized to determine formation of myotubes. The fusion index for myotube formation 
was calculated using the following formula:   
   Fusion index   
  umber of nuclei per myotube (two or more nuclei)
Total number of nuclei
  100 
 
2.2.8. Western blotting 
We performed electrophoretic separation of proteins from C2C12 lysates prepared on day 0 (in 
growth media), day 5 (in differentiation media) of control and HGF (2, 10, 50 ng/ml) treated 
cultures. Proteins (30 µg) were loaded onto 12.5% Tris/Glycine reducing SDS-PAGE and 
transferred onto nitrocellulose membrane (Life Sciences, South Africa, cat.P/N 66485) for 
Western Blot.  Primary antibodies and dilutions used were as follows:  monoclonal mouse anti-
vinculin antibody (Sigma, USA, cat.V9131; 1:2000); mouse anti-MyHC (MF-20) 
(Developmental Studies Hybridoma Bank, USA, cat.M29; 1:100); mouse monoclonal α-tubulin 
(Santa Cruz, USA, cat.sc-5286; 1:50). Anti-mouse (Dako, Denmark, cat.P-0260) or anti-rabbit 
(Dako, Denmark, cat.P-0448) HRP conjugated secondary antibodies were used at 1:8000 and 
1:4000, respectively. (Incubation times in primary and secondary antibodies were 2 h and 1 h, 
respectively). HRP activity was visualized using Enhanced Chemiluminescence (ECL) (Bio-Rad, 
USA, cat.170-570) and GeneSys Image Acquisition software (Vacutec, South Africa). 
Densitometry analysis was done using the Versa Doc Imaging System (Bio-Rad, USA) and a 
computer program called Quantity One and ImageJ. 
2.2.9. Statistics 
All statistical analysis was performed with either a Student’s t-test for parametric data or a Mann-
Whitney-U test for non-parametric data, with values of p<0.05 considered statistically significant. 
The results from each experiment were expressed as Mean ± standard error of the mean (SEM). 





This study investigated the effect of HGF on C2C12 myoblast proliferation, migration and 
differentiation. In all experiments; 0, 2, 10 and 50 ng/ml HGF was tested, as these represented the 
range of doses used in literature. Proliferation was investigated via two quantitative methods 
namely, manual cell counts and the crystal violet assay. Following proliferation, we focused on 
analysing the effect of HGF on C2C12 myoblast migration, using a scratch assay. Finally we 
investigated the role of HGF in C2C12 myoblast differentiation via analysis of myotube formation 




) and the structural 
protein MyHC. 
2.3.1. HGF affects C2C12 myoblast proliferation in a dose-dependent manner 
Study of the proliferative capacity of myoblasts aids in the understanding of the functionality of the 
cells (Anastasi, 1997). Therefore, to assess the proliferative capacity of C2C12 myoblasts upon 
exposure to 0, 2, 10 and 50 ng/ml HGF, we used two quantitative assays, namely manual cell 
counts and the crystal violet assay. Brightfield analysis revealed that the confluence of the cells was 
lowest at 10 ng/ml HGF compared to untreated control, 2 and 50 ng/ml HGF (Figure 2.1A), 
suggesting that C2C12 myoblast proliferation capacity was down-regulated in response to 10 ng/ml 
HGF.  
Quantification revealed a dose-dependent effect of HGF on C2C12 cell number in both assays.  
Cells treated with 2 ng/ml HGF showed a significant increase in cell number (2.27 ± 0.146 x 10
5 
cells) compared to the untreated control (1.74 ± 0.189 x 10
5
 cells, p<0.01).  This increase was also 
significant compared to 50 ng/ml HGF (1.84 ± 0.186 x 10
5 
cells, p<0.01). A significant decrease in 
cell number (1.15 ± 0.145 x 10
5
 cells) was demonstrated when cells were treated with 10 ng/ml 
HGF compared to control (p<0.01). This effect was also significant compared to cells treated with 
2 ng/ml and 50 ng/ml HGF (p<0.01) (Figure 2.1B).   
Utilisation of the crystal violet assay confirmed the dose-dependent effect of HGF on C2C12 cell 
number. A small non-significant increase in cell number at 2 ng/ml HGF (7.87 ± 1.08 x 10
4 
cells) 
was detected compared to the untreated control (7.41 ± 1.20 x 10
4 
cells). However, HGF (10 ng/ml) 
resulted in a significant decrease in cell number (5.79 ± 0.572 x 10
4 
cells) compared to both 
untreated control and 2 ng/ml HGF (p<0.05). At 50 ng/ml, cell numbers approached control values 
(7.02 ± 0.236 x 10
4 
cells) and were significantly increased compared to 10 ng/ml HGF (p<0.05) 










































































































Figure 2.1: Proliferation of C2C12 myoblasts in response to HGF. Equal numbers of cells were plated and cultured for 24 h under proliferation 
conditions, followed by treatment with HGF for a further 24 h. A) Phase contrast images indicate the confluence levels of C2C12 myoblasts under 
different HGF concentrations (0, 2, 10 or 50 ng/ml). Images were captured using Motic 2.0 camera at 40 X magnification. Scale bar = 10 µm. B) Analysis 
of proliferation via cell counts. C) Analysis of proliferation via crystal violet assay. ** p<0.01, *p<0.05. All data is mean ± SEM. n=6. 
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To confirm that the decrease in proliferation observed at 10 ng/ml was not due to apoptosis, we 
performed a live-dead assay i.e. Trypan blue assay (Figure 2.2). Images of cells cultured in the 
absence of serum (positive control) revealed fewer cells per field of view; however, both control 
and HGF-treated (10 ng/ml) cells appeared to have similar cell numbers (Figure 2.2A). Trypan 
blue viability demonstrated a significant decrease in viability in serum free conditions (61.3 ± 
4.41%) compared to control (89 ± 4.58, p<0.05) (Figure 2.2B). However, in response to HGF no 
significant difference in percentage dead cells (13 ± 1.68) was seen compared to control (11 ± 
5.57) (Figure 2.2B). Together, the trypan blue and morphological assessments suggest that the 
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Figure 2.2: Trypan blue assay of C2C12 cells under different growth media conditions. C2C12 myoblasts were cultured in normal growth media for 24 h 
followed by replacement with either growth media, serum-deprived or growth media containing 10 ng/ml HGF for a further 24 h. The arrows indicate distinct 
morphologies observed under different conditions. A) Phase contrast images of C2C12 cells under different culture conditions captured using Motic 2.0 camera at 
40 X magnification. Scale bar = 10 µm. B) Trypan blue viability test under different growth media conditions. *p<0.05; **p< 0.01. All data is mean ± SEM, n=3 
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2.3.2. HGF affects vinculin expression in proliferating C2C12 myoblasts in a dose-dependent 
manner. 
Given the decreased C2C12 proliferation observed in response to 10 ng/ml HGF, examination of 
the expression of vinculin in these cells would aid in understanding the mechanism via which HGF 
affects proliferation. HGF-treated C2C12 lysates were electrophoretically separated, and transferred 
onto nitrocellulose membrane, followed by probing with anti-vinculin antibody. Cells treated with 
10 ng/ml HGF had the most prominent vinculin expression levels compared to the untreated 
control, 2 ng/ml and 50 ng/ml HGF (Figure 2.3A).  Densitometry analysis revealed an insignificant 
decrease in vinculin expression in response to 2 ng/ml HGF (0.693 ± 0.237) compared to untreated 
control (0.958 ± 0.18), and an increase in vinculin expression in response to 10 ng/ml HGF (1.13 ± 
0.07) compared to untreated control. A significant increase in vinculin expression was observed in 
response to 10 ng/ml compared to 2 ng/ml HGF (p<0.05) (Figure 2.3B). Since changes in vinculin 
expression in response to HGF are a necessary step in satellite cell progression through the cell 
cycle, this data suggests a possible regulation of myoblast proliferation by HGF through vinculin 
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Figure 2.3: Vinculin expression in proliferating C2C12 myoblasts treated with 2, 10, 50 ng/ml 
HGF. A) Band intensities of vinculin observed in response to 0, 2, 10 and 50 ng/ml HGF. B) 





2.3.3. HGF regulates the percentage wound closure of C2C12 myoblasts 
To test the effect of HGF on C2C12 myoblast migration, we utilized the scratch assay (Goetsch and 
Niesler, 2011) and calculated the percentage wound closure and the rate of migration over a 7 h 
period. HGF (10 ng/ml and 50 ng/ml) was observed to decrease the wound size, suggesting 
increased migration (Figure 2.4A).  
Following 3 h post-wounding, there was a significant increase in percentage wound closure in 
response to 10 ng/ml HGF (29 ± 3.98%)  compared to 2 ng/ml HGF (17.6 ± 3.22%, p<0.05). 
Following 5 h, there was a significant increase in percentage wound closure at 10 ng/ml HGF (51 ± 
2.13%) compared to untreated control (36.4 ± 3.71%, p<0.01). This increase was also significant 
compared to 2 ng/ml (31.1 ± 4.65%, p<0.01) and 50 ng/ml HGF (39.3 ± 3.22%, p<0.05). Finally, 
after 7 h, HGF (10 ng/ml) significantly increased migration (65.8 ± 3.67%) compared to untreated 
control (50.2 ± 3.12%, p<0.05) and 2 ng/ml HGF (43.4 ± 4.83%, p<0.01). At 50 ng/ml, HGF did 
not significantly change migration compared to untreated control (Figure 2.4B). 
The rate of migration over the 7 h period (Figure 2.4C) was determined by calculating gradients 
from the percentage wound closure graph (Figure 2.4B). HGF significantly increased the rate of 
migration in response to 10 ng/ml (8.718 ± 0.609%/h, p<0.05) and decreased the rate of migration 
at 2 ng/ml HGF (6.016 ± 1.098%/h, p<0.05) compared to untreated control (7.194 ± 0.638%/h).  
HGF (50 ng/ml) did not significantly change rate of wound closure in comparison to untreated 
control, however, a significant increase in migration rate was seen compared to 2 ng/ml HGF 
(8.219 ± 0.54%/h, p<0.05) (Figure 2.4C). Interestingly, the graphical analysis of the effect of HGF 
on the rate of migration (Figure 2.4C) resembled a similar trend as the vinculin expression data 
(Figure 2.3B), where both graphs showed an increase in vinculin expression and rate of migration 
































































































Figure 2.4: HGF increases migration of C2C12 myoblasts. A) Phase contrast images of wound closure in 
C2C12 myoblasts following incubation with different doses of HGF (40 X magnification). A scratch assay 
was performed and cells treated with 0, 2, 10 or 50 ng/ml HGF. The white lines within the images highlight 
the scratch front. Images at 0 and 7 h are shown. Scale bar = 10 µm. B) Graph of percentage wound closure 
over 7 h. ** = p<0.01, * = p<0.05. C) Graph of rate of migration generated from the gradients of Figure 2.4 
B. All data is mean ± SEM. # indicates significant difference between 2 and 10 ng/ml HGF; * indicates a 
statistical significance between 0 and 10 ng/ml HGF; $ indicates a statistical significance between 10 ng/ml 
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2.3.4. HGF dose-dependently regulates vinculin intensity in migrating C2C12 myoblasts 
Here we sought to further determine the mechanism underlying the effect of HGF on C2C12 
myoblast migration. Using immunocytochemistry, we assessed vinculin intensity levels in cells at 
the leading front following 7 h incubation with 0, 2, 10 and 50 ng/ml HGF. Confocal imaging 
revealed that all the cells showed vinculin labelling. Increased vinculin levels were observed in 
response to 10 ng/ml HGF compared to untreated control, where cells formed large vinculin 
positive plaques at their leading fronts. However, cells treated with 2 ng/ml HGF expressed 
vinculin at similar levels to untreated control (Figure 2.5A).  
Quantification of vinculin intensity revealed that the effect of HGF followed a hyperbolic shape. 
A significant increase in vinculin intensity level in cells treated with 10 ng/ml HGF (0.764 ± 
0.277) and 50 ng/ml HGF (0.575 ± 0.158) compared to untreated control (0.246 ± 0.157, p<0.01) 
and 2 ng/ml HGF (0.387 ± 0.237, p<0.01). The vinculin intensity levels at 2 ng/ml HGF was not 
different to untreated control (Figure 2.5B). These findings highlight that HGF dose-dependently 
regulates vinculin expression in migrating C2C12 myoblasts; this may contribute to the 
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Figure 2.5: Vinculin expression in HGF-treated migrating C2C12 myoblasts. A) Cells were scratched and allowed to migrate for 7 h followed by 
fixation, immunocytochemistry and analysis using the Zeiss Confocal microscope at 40 X magnification. Scale bar = 20 µm. Red indicates vinculin 
whilst the blue indicates the cell nuclei stained with Hoechst. The white lines within the images highlight the scratch front. B) Vinculin expression levels 
in migrating cells were assessed relative to control using ImageJ. All data is mean ± SEM. n=3. ** p<0.01. 
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2.3.5. Pax7 expression levels in differentiating C2C12 cells are regulated by exogenous HGF 
We next examined whether HGF induces dose-dependent changes in the expression of Pax7 
transcription factors. Pax7 is implicated in specification of myogenic linage and its down-regulation 
is necessary for differentiation to occur (McFarlane et al., 2008). Cells were cultured to 80% 
confluence then switched to differentiation media containing 0, 2, 10 and 50 ng/ml HGF and 
cultured for 3 days; Pax7 expression was then analysed by confocal microscopy on day 1, 2 and 3. 
Pax7 expression was observed to be maintained longer in response to 2 ng/ml HGF compared to 
untreated control. In contrast, in response to 10 ng/ml HGF, Pax7 was down-regulated earlier than 
untreated control (Figure 2.6).  
Pax7 expression on day one post-differentiation increased in response to 2 ng/ml HGF (61.4 ± 
16.6%)  relative to untreated control cells (40.8 ± 10.2%), but this was not statistically significant 
(Figure 2.7). On day 2, a reduction in Pax7 expression was observed in response to 10 ng/ml HGF 
compared to untreated control levels (Figure 2.7); this decrease was significant (22.4 ± 0.88%) 
compared to untreated control (35.8 ± 5.75%, p<0.05) and 50 ng/ml HGF (28.4 ± 1.35%, p<0.01).  
Cells treated with HGF (2 ng/ml) showed higher Pax7 levels (43 ± 6.79%) compared to untreated 
control. On day 3, Pax7 expression was almost undetectable in untreated control (3.66 ± 2.16%) as 
well as cells treated with 10 ng/ml HGF (2.79 ± 1.5%) and 50 ng/ml HGF (2.16 ± 0.71%) cells. 
However, HGF (2 ng/ml) showed greater (maintained) Pax7 expression (13.6 ± 2.88%, p<0.01) 


























Figure 2.6: Pax7 expression of C2C12 myoblasts in response to HGF on day 1, 2 and 3 post differentiation. Cells were allowed to 
differentiate for 1-3 days followed by fixation, immunocytochemistry at then analysis using the Zeiss confocal microscope. Scale bar = 20 µm. 
Blue indicates the Hoechst nuclear stain, red indicate Pax7.  
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Figure 2.7: Percentage Pax7
+
 differentiating C2C12 cells in response to HGF. Cells were cultured in 
growth media until they were 80% confluent. Differentiation media was then added and cells were fixed with 
4% paraformaldehyde at day 1, 2, 3 and then probed with anti-Pax7 antibody. Five random fields of view were 
observed for each treatment (from Figure 2.6) and quantified using ImageJ. ** p<0.01, *p<0.05. All data is 









2.3.6. MyoD expression levels in differentiating C2C12 cells are regulated by exogenous HGF 
MyoD is a transcription factor expressed in cells committed to differentiation (McFarlane et al., 
2008); (Buckingham et al., 2006); (Seale et al., 2004). Cells were cultured to 80% confluence then 
switched to differentiation media containing 0, 2, 10 and 50 ng/ml HGF and cultured for 3 days; 
MyoD expression was analysed by confocal microscopy at day 1, 2 and 3.  
At day 1 of differentiation a notable increase in nuclear MyoD expression was observed in response 
to 10 ng/ml HGF compared to untreated control cells. On day 2, cells exposed to 10 ng/ml HGF 
continued to show higher MyoD expression compared to untreated control cells, but expression was 
observed to decline by day 3. In response to 2 ng/ml HGF, cells appeared to display lower intensity 
of MyoD compared to control (Figure 2.8).  
Quantification of MyoD expression showed that there was a significant decrease in percentage 
MyoD expressing cells in response to 2 ng/ml HGF (24.5 ± 1.65%) compared to untreated control 
(32.6 ± 3.33%, p<0.01). At 10 ng/ml we found a significant increase in MyoD positive cells 
compared to untreated control (p<0.01). Cells treated with 50 ng/ml HGF also showed a significant 
increase in the percentage of MyoD expression (p<0.01) compared to untreated control. On day 2 
an overall increase in percentage MyoD expressing cells was observed under all conditions 
compared to day 1. The greatest percentage was seen in response to 10 ng/ml HGF (69.9 ± 6.08%), 
and this increase in MyoD was significant compared to 2 ng/ml HGF (p<0.01) and 50 ng/ml HGF 
(p<0.05). On day 3 a decrease in MyoD expression was demonstrated compared to expression 
levels observed on day 1 and 2. A significant change in percentage MyoD expressing cells was 
demonstrated in response to 2 ng/ml HGF (30.3 ± 2.23%) compared to 50 ng/ml HGF (38.3 ± 
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Figure 2.8: MyoD expression of C2C12 myoblasts in response to HGF on day 1, 2 and 3 post differentiation. Cells were allowed to 
differentiate for 1-3 days followed by fixation, immunocytochemistry at then analysis using the Zeiss confocal microscope. Scale bar = 20 µm. 























































































Figure 2.9: Percentage MyoD positive differentiating cells in response to HGF. Cells were cultured in growth 
media until they were 80% confluent. Differentiation media was then added and cells were fixed with 4% 
paraformaldehyde at day 1, 2, 3 and then probed with anti-MyoD antibody. Five random fields of view were observed 





2.3.7. HGF affects C2C12 myoblast differentiation in a dose-dependent manner 
 
The process of differentiation includes fusion of individual myoblasts to form myocytes and 
eventually multinucleated myotubes. We therefore monitored this process in the presence of 
exogenous HGF at 0, 2, 10 and 50 ng/ml. Brightfield images revealed that cells cultured in 10 
ng/ml HGF formed longer myotubes compared to those cultured in 0, 2 and 50 ng/ml HGF (Figure 
2.10A), suggesting that C2C12 differentiation capacity was up-regulated in response to10 ng/ml 
HGF. The differentiation of C2C12 cells into myotubes was then confirmed by staining with 
Phalloidin (Figure 2.10B) and immunocytochemistry with myosin heavy chain (MyHC) (Figure 
2.10C). Both Phalloidin and MyHC staining confirmed an increase in myotubes in response to 10 
ng/ml HGF and a decrease in response to 2 ng/ml HGF (Figure 2.10B and C).  
Assessment of the differentiation index demonstrated a significant increase in differentiation in 
response to 10 ng/ml HGF (53.7 ± 3.84%) compared to control (40.7 ± 4.77%, p<0.05). This 
increase in differentiation was also significant compared to 2 ng/ml HGF (30.3 ± 2.86%, p<0.01) 
and 50 ng/ml HGF (38.4 ± 4.77%, p<0.01). A decrease in differentiation was detected at 2 ng/ml 
compared to untreated control (p<0.05), 10 ng/ml HGF (p<0.01) and 50 ng/ml HGF (p<0.05) 
(Figure 2.11A). 
Determination of the fusion index confirmed a significant increase in fusion in response to 10 ng/ml 
HGF (47.7 ± 7.58%) compared to untreated control (35.9 ± 3.25%, p<0.05), 2 ng/ml HGF (29.4 ± 
1.63%,  p<0.01) and 50 ng/ml HGF  (32.6 ± 4.39%,  p<0.01). A decrease in fusion was shown at 2 
ng/ml HGF compared to untreated control (p<0.01). Cells treated with 50 ng/ml HGF also revealed 
a significant decrease in fusion index (p<0.01) compared to 10 ng/ml HGF (<0.01), but displayed a 


























Figure 2.10: Myotube formation in differentiating C2C12 myoblasts treated with 0, 2, 10 or 50 ng/ml HGF. Cells were allowed to differentiate for 5 
days followed by fixation, staining with Phalloidin-TRITC or immunocytochemistry with MyHC and analysis using the Zeiss Confocal microscope at 40 X 
magnification. Scale bar = 20 µm. A) Phase contrast images of differentiating cells at day 5. B) Confocal images of myotubes, blue indicates the Hoechst 
nuclear stain, orange indicates Phalloidin. C) Confocal images of myotubes, blue indicates the Hoechst nuclear stain, red indicates MyHC staining myotubes; 
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Figure 2.11: Differentiation and Fusion index of C2C12 myoblasts following  treatment with 0, 2, 10 or 50 ng/ml HGF. A) The differentiation index 
(i.e. percentage MyHC positive cells (myocytes and myotubes)) was analysed for each of the HGF treatments using ImageJ software. B) The fusion index 
(i.e. percentage myotubes formed, two or more nuclei) was analysed for each of the HGF treatments using ImageJ software. ** p<0.01, *p<0.05. All data is 
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2.3.8. Expression of Myosin Heavy Chain (MyHC) during terminal differentiation is regulated by 
HGF 
Given the increased C2C12 differentiation and fusion observed in response to 10 ng/ml HGF 
(Figure 2.10 and 2.11), we aimed to verify these observations via western blot analysis. HGF-
treated C2C12 lysates were electrophoretically separated, and transferred onto nitrocellulose 
membrane, followed by probing with anti-MyHC antibody. The density of immunoreactive MyHC 
band was strongly prominent in response to 10 ng/ml HGF compared to the untreated control, 2 and 
50 ng/ml HGF. Cells treated with 50 ng/ml HGF demonstrated less MyHC expression compared to 
untreated control and 2 ng/ml HGF (Figure 2.12A).  
Band intensities were quantified relative to control using densitometry. Results revealed a 
significant increase in MyHC expression at 10 ng/ml HGF (1.49 ± 0.06) compared to untreated 















Figure 2.12: Myosin heavy chain (MyHC) expression in differentiating C2C12 myoblast in response 
to HGF. Cells were allowed to differentiate for 5 days; lysates were harvested and run on SDS-PAGE 
followed by western blot analysis. A) Band intensities observed for MyHC on day 5 lysates. B) 
Corresponding densitometry analysis of MyHC expression relative to untreated control. *p<0.05. All data is 
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Satellite cells are quiescent skeletal muscle cells that play a pivotal role in maintenance, 
myogenesis and repair of the skeletal muscle (Boldrin et al., 2010). Quiescent and activated satellite 
cells express Pax7; however, upon the onset of differentiation, they down-regulate Pax7 and up-
regulate MyoD and myogenin (Olguin and Pisconti, 2012). Satellite cells are activated by different 
environmental cues including growth factors, such as FGF and HGF. HGF has been shown to be 
involved not only in satellite cell activation, but also in proliferation, migration, and differentiation 
and is a key regulator of skeletal muscle regeneration (Tatsumi and Allen, 2004). 
Satellite cell proliferation is an important process in skeletal muscle repair and regeneration, 
however, in vitro the effect of HGF on proliferation is highly dose-dependent (Yamada et al., 
2010a, Gal-Levi et al., 1998). Yamada et al. demonstrated that high levels of HGF (over 10 ng/ml) 
suppress the proliferative activity of rat satellite cells (Yamada et al., 2010a). Gal-Levi et al. came 
to similar conclusions using the chicken skeletal muscle cells and C2 cells. They found a reduction 
in activation of quiescent satellite cells and decreased growth upon exposure to exogenous HGF (20 
and 50 ng/ml) (Gal-Levi et al., 1998). Our data confirms that there is a dose-dependent effect of 
HGF on C2C12 myoblast proliferation. Our cell count and crystal violet assay showed similar 
trends in terms of the dose-dependent effect of HGF on proliferation. In both assays, HGF (2 ng/ml) 
stimulated proliferation, however, 10 ng/ml HGF resulted in a significant decrease in proliferation 
compared to the untreated control. The decrease in cell number in response to 10 ng/ml is unlikely 
to be due to cell death; hence we speculate that somewhere between 2 and 10 ng/ml HGF there 
might be a threshhold dose that supresses proliferation.  
HGF has been shown to regulate satellite cell proliferation via two independent pathways i.e. 
Ras/Raf pathway and Stat3 pathway (Birchmeier et al., 2003, Kim et al., 2011). Based on the 
increase and decrease in proliferation in response to 2 ng/ml and 10 ng/ml HGF, respectively, we 
suspect involvement of these two pathways that contributes to this dose-dependent effect 
(Birchmeier et al., 2003, Kim et al., 2011). Other studies have shown that HGF receptor (c-Met) 
coupling to MAPK/ERK pathway via the adaptor, Grb2, plays a role in stimulating proliferation 
(Leshem et al., 2002). In accordance with these findings, we suspect a similar mechanism at lower 
HGF dose (2 ng/ml) where an increase in proliferation is observed. Short-lived activation of MAPK 
in C2 cell line was demonstrated to stimulate proliferation whilst sustained activation leads to 




induced this short-lived activation of MAPK which resulted in increased proliferation and 
decreased differentiation. 
Analysis of the percentage wound closure further indicated that HGF (10 ng/ml) (while decreasing 
proliferation), stimulated migration. HGF is known to promote satellite cell migration to the site of 
injury via activation of  the Ras/Raf pathway or MAPK/ERK cascade (Charge and Rudnicki, 2004). 
The smaller decrease in response to 2 ng/ml HGF may be a reflection of the increased proliferation 
observed at this concentration.  
We next examined the effect of HGF on the localization and expression of scaffold protein, 
vinculin. Vinculin is a ubiquitously expressed actin filament binding protein that localizes in focal 
adhesions; is known to be actively involved in myoblast proliferation and migration (Le Clainche 
and Carlier, 2008). Vinculin expression levels have been shown to be higher in migrating cells 
(Moon et al., 2004). Vinculin image quantification and vinculin protein expression analysis 
(Western blot) both reviewed that cells treated with 10 ng/ml HGF showed high vinculin expression 
levels, which correlated with both an increased percentage in wound closure and a decrease in 
proliferation. Since cells treated with 50 ng/ml HGF showed no change in the rate of migration and 
increased proliferation, we speculate that increased proliferation may not necessarily correlate to 
migration as is commonly thought in literature, however, this requires further investigation.  Our 
results therefore indicate that HGF increases vinculin expression and increased vinculin expression 
in turn promotes migration, but decreases proliferation of C2C12 myoblasts in a dose-dependent 
manner, an important mechanism that is essential during in vivo wound healing.   
Myoblast differentiation is essential during skeletal muscle repair and formation and is detected by 
the up-regulation of MRFs such as MyoD and down-regulation of Pax7 (Gal-Levi et al., 1998a, 
Gal-Levi et al., 1998b). To examine the effect of HGF on myoblast differentiation, we firstly 
examined expression of MyoD and Pax7 over 3 days of differentiation. Our data suggests that 
MyoD promotes myoblast progression to terminal differentiation when cells are exposed to 10 
ng/ml HGF. At this concentration, the cells showed significantly increased percentage MyoD cells 
at day 1. Furthermore, a remarkably reduced Pax7 expression, a necessary step for cells to exit 
proliferation and enter the differentiation phase (Knapp et al., 2006); (Gal-Levi et al., 1998a, Gal-
Levi et al., 1998b) was observed at day 2.  The early and high expression levels of MyoD at 10 
ng/ml indicated early promotion of C2C12 myoblast entry into differentiation at this HGF 




correlate with other findings that MyoD expression is induced in satellite cells in response to HGF 
treatments (15 ng/ml) in rat soleus muscle (Ishido and Kasuga, 2012).  
Maintenance of Pax7 expression is essential for self-renewal (Gill et al., 2010) but delays 
differentiation  (Zammit et al., 2006b). We observed that cells treated with 2 ng/ml showed 
maintenance of Pax7 expression throughout day 1, 2 and 3 of differentiation; this suggests that 
HGF at this concentration can delay differentiation in a portion of the cell population by promoting 
Pax7 expression. Zammit et al., reported that expression of Pax7 delays onset of differentiation 
through delayed expression of myogenin (Zammit et al., 2006a). Consistent with these findings, 
Olguin et al., 2012 showed that expression of Pax7 in adult primary myoblasts down regulates 
MyoD and prevents myogenin induction leading to delayed differentiation (Olguin and Pisconti, 
2012). We therefore suspect that the delayed differentiation we observed in response to HGF (2 
ng/ml) might be through delayed induction of myogenin; however, this requires further 
investigation.  
To confirm the effect of HGF on terminal differentiation we assessed myotube formation after 5 
days of differentiation. Previous studies have shown that the addition of exogenous HGF to satellite 
cells dose-dependently inhibits the expression of MyHC, which is expressed late in muscle 
differentiation (Miller et al., 2000, Bandow et al., 2004). In our study the HGF concentrations that 
increased proliferation (i.e. 2 ng/ml) showed less stimulatory effect on terminal differentiation as 
compared to 10 ng/ml HGF, which had the highest effect on promoting differentiation and 
decreased proliferation. HGF is known to inhibit myoblast differentiation into myofibers via its 
inhibitory effect on the activity of MyoD and myogenin (Gal-Levi et al., 1998a, Bandow et al., 
2004, Gal-Levi et al., 1998b). Other studies have shown that HGF receptor coupling to 
MAPK/ERK pathway via the adaptor, Grb2, plays a role in inhibiting myoblast differentiation and 
stimulating proliferation (Leshem et al 2002). Additionally, in vitro studies suggest that the binding 
of HGF to its receptor c-Met dose-dependently results in the silencing of MyoD and myogenin gene 
expression and inhibits the synthesis of muscle specific structural protein, MyHC as well as 
myotube formation (Anastasi, 1997). The increased differentiation and fusion index as well as 
elevated MyHC expression observed in response to HGF (10 ng/ml) correlated well with the 

















In summary, we have demonstrated dose-dependent effects of HGF on C2C12 myoblast 
proliferation, migration and differentiation and provide evidence that HGF participates in all these 
myogenic processes. C2C12 myoblast proliferation rates are increased or decreased by HGF at 2 
ng/ml and 10 ng/ml respectively. The decrease in proliferation at 10 ng/ml HGF which shows an 
up-regulation of vinculin expression level correlates with the initiation of cell migration, revealed 
by the increase in migration at 10 ng/ml HGF. Importantly, HGF causes divergent effects on 
migration as well as differentiation. HGF (2 ng/ml) resulted in increased proliferation, but 
registered a decrease in both migration and differentiation. A dose-dependent effect of HGF on 
differentiation was observed, with 10 ng/ml showing increased MyoD and MyHC expression 
accompanied by down-regulation in Pax7. However, most of the dose-dependent effects of HGF on 
myogenesis did not follow the classical hyperbolic shape. We conclude that the ability of HGF to 
alter activity of the myogenic processes is supportive of its role in skeletal muscle regeneration, 
providing further evidence that HGF plays a key role in regulation of wound repair and 
regeneration and is a potential drug target for muscle disease.  
 
 
Figure 2.13: Summary of findings of the effect of HGF on C2C12 myoblast proliferation, migration 
and differentiation. Myoblast proliferation was elevated and reduced in response to 2 ng/ml and 10 ng/ml 
HGF, respectively, via vinculin expression analysis. Migrations studies revealed that HGF stimulated and 
reduced the migratory activity of C2C12 myoblasts in an opposite effect to proliferation. During both early 
and terminal differentiation, HGF (2 ng/ml) up-regulated Pax7 expression and down-regulated MyoD and 
MyHC expression. Opposite effects were observed in response to 10 ng/ml HGF; there was down-regulation 






THE EFFECT OF HEPATOCYTE GROWTH FACTOR (HGF) ON HUMAN 
SKELETAL MYOBLAST PROLIFERATION AND DIFFERENTIATION 
ABSTRACT 
Hepatocyte growth factor (HGF), a pleiotrophic cytokine has been previously reported to 
dose-dependently regulate mouse myoblast proliferation, migration and differentiation, but 
the fact whether HGF has the same effect on primary cultured human skeletal myoblasts 
(HSkM) is not known. In this context, the objective of this study was to investigate the effect 
of HGF (2 and 10 ng/ml) on HSkM myoblast proliferation and differentiation. Cell counts 





 expression was used to determine myogenic commitment. Terminal 
differentiation was assessed through total MyHC expression analysis. We demonstrate that 
treatment of HSkM with a low HGF concentration (2 ng/ml) promotes proliferation and 
decrease differentiation. In contrast, treatment of HSkM cells with a higher HGF 
concentration (10 ng/ml) decreases proliferation, but promotes differentiation. These findings 
confirm previous work in C2C12 myoblasts.  Since HSkM cells represent a more accurate in 
vitro model, these findings highlight the importance of HGF in the skeletal muscle and further 
underscore the role of HGF as a central regulator of myogenesis. 
 











3.1.  INTRODUCTION 
The immortalized C2C12 cell line is a valuable tool for the identification of mechanisms related to 
myogenic processes; however, this model does not necessarily represent the complexity of skeletal 
muscle physiology (Peault et al., 2007). In most cases, the mutations found in mouse cell lines are 
very different to those in human cells; for example, a mutation in the dystrophin gene reflects as a 
mild pathological phenotype in mice, but in humans it can cause an advanced and fatal disease 
(Mamchaoui et al., 2011). As such, use of human primary culture often represents a more accurate 
in vitro model (Martin et al., 2009).  
Primary culture of human skeletal myoblasts (HSkM) allows analysis of the sequential processes 
during skeletal muscle regeneration, signal transduction and metabolism (Martin et al., 2009); 
(Mamchaoui et al., 2011). Furthermore, these cells are candidates for transplantation therapies to 
treat diseases such as muscular dystrophies or severe muscle trauma (Peault et al., 2007). They 
serve as a powerful tool for investigating pathological mechanisms (including those associated with 
muscle) and for developing cell-based biotherapies (Mamchaoui et al., 2011). 
In skeletal muscle, the balance between myogenic precursor proliferation and differentiation is 
influenced by growth factors including FGF and HGF. HGF elicits several signalling cascades, 
mainly through c-Met receptor phosphorylation which terminates in the nucleus with the activation 
of specific transcription factors (Pax7, Myf5, MyoD and myogenin) (Goel and Dey, 2002). 
Findings from in vitro experimentation and animal models suggest that HGF is a major inducer of 
satellite cell activation and proliferation (Morgan and Partridge, 2003, Gal-Levi et al., 1998b). 
Similar observations were demonstrated by us in chapter 2. Human studies by O’Reilly et al. 
demonstrated activation of satellite cells in human skeletal muscle associated with increased HGF 
as early as 24 h post-exercise (O'Reilly et al., 2008).  
Differentiation and fusion of myoblasts is critical to the development of mature multinucleated 
skeletal muscle myotubes, and during these processes, the myoblasts exit the cell cycle and their 
mitotic activity ceases (Charge and Rudnicki, 2004).  HGF has been reported to impair 
differentiation in animal models (Gal-Levi et al., 1998b). O’Reilly et al. reported for the first time 
that in the human skeletal muscle, down-regulation of active HGF is a necessary step for 
differentiation to occur (O'Reilly et al., 2008). However, not much more is known regarding the 




Previously, we established a dose-dependent effect of HGF on C2C12 myoblast proliferation and 
differentiation (see Chapter 2).  To date, most HGF studies in skeletal muscle regeneration and 
repair have focused mainly on mouse and rat primary culture and immortalised cell lines. The 
present study was therefore designed to investigate the role of HGF on human primary cultured 
skeletal myoblast proliferation and differentiation. Human recombinant HGF was tested at 2 and 10 
ng/ml as these were the concentrations that revealed significant differences in C2C12 mouse 
myoblast studies (see Chapter 2). Furthermore, we investigated the underlying molecular 





















3.2. EXPERIMENTAL PROCEDURE 
3.2.1. Cell culture 
Human primary cultured myoblasts (HSkM) were purchased from Lonza, USA (cat.CC-2561). The 
cells were isolated from the upper arm or leg muscle tissue of normal donors. They were contained 
in a Clonetics® Skeletal Muscle System composed of optimized growth media. The cells were 
cultured in Skeletal Muscle Cell Medium BulletKit® (Lonza, USA, cat.CC-3160) during passage 1 
and 2. From passage 3 HSkM were cultured in human myoblast growth media which consisted of 
HAMS-F10 (Life Technologies, South Africa, cat.31550-015) supplemented with 10% (v/v) fetal 
bovine serum (Biowest, USA, cat.S181H-500), 2% (v/v) L-glutamine (Lonza, USA, cat.BE17-
605E) and 2% (v/v) Penicillin-Streptomycin (Lonza, USA, cat.DE17-602E) and 2.5 ng/ml FGF 
(Promega, USA, cat. G507A). For differentiation studies, monolayers of HSkM cells were 
expanded until they were 80% confluent then switched from growth media to differentiation media 
(HAMS-F10 supplemented with 2% (v/v) horse serum) (Biowest, USA, cat.S090H-100). Human 
HGF (PeproTech, USA, cat.100-39) was used at a final concentration of 2 and 10 ng/ml to assess 
effect on proliferation and differentiation. HSkM cells were incubated at 37
o
C in a humidified 
atmosphere at 5% CO2. All experiments were carried out under sterile conditions in a Class II 
Biohazard Safety Cabinet. Passages 2-3 were used for all experiments. 
 
3.2.2. Proliferation Assay (TC-20 Automated Counter) 
Cells were grown to initial densities of 5 x 10
4
 cells/well in 6 well tissue culture plate containing 
growth media and incubated at 37
o
C, 5% CO2 for 24 h. HGF (0, 2 and10 ng/ml) was then added to 
cells and they were incubated for a further 24 h. Thereafter, cells were trypsinised for 5 min and a 
small sample (10 µl) was removed and transferred onto a counting slide (Bio-rad, USA, cat.145-
0011). The slide was inserted into a TC-20™ Automated cell counter (Biorad, USA, 









Differentiated cells were fixed in 4% paraformaldehyde containing 0.1% Triton X-100 (Sigma, 
Germany, cat.T9284) for 20 min and blocked with 5% donkey serum (Biowest, USA, cat.S2170-
100) for 30 min. Primary antibodies were added overnight and dilutions used were as follows: 
monoclonal goat anti-Pax7 antibody (Santa Cruz, USA, sc-7748; 1:500), rabbit polyclonal anti-
MyoD (Santa Cruz, USA, cat.sc-760; 1:100), monoclonal mouse MF-20 (Developmental 
Hybridomal Studies, USA, cat.MF29; 1:100). DyLight 488-conjugated AffiniPure donkey anti-
rabbit IgG (Jackson ImmunoResearch, USA, cat.CN-711-485-152), DyLight 488-conjugated 
AffiniPure donkey anti-mouse lgG (Jackson ImmunoResearch, USA, cat.CN-715-485-151) and 
DyLight 594-conjugated AffiniPure donkey anti-goat lgG, secondary antibodies (Jackson 
ImmunoResearch, USA, cat.CN-715-515-151) were used at 1:1000 to detect appropriate primary 
antibodies and incubated for 1 h. Hoechst nuclei stain (Sigma, Germany,cat.B2261; 10 µg/ml stock, 
1:2000) was added to all the cells for 5 min. Moviol was used as the mounting agent. All images 
were captured using the Zeiss 710LSM confocal microscope (Germany).  
 
3.2.4. Quantification of MyoD and Pax7+ myoblasts 
Five random fields of view of differentiated cells (> 30 cells/ field) were captured using the Zeiss 
710LSM confocal microscope and analysed with ImageJ software (http://rsbweb.nih.gov/ij/). The 
percentage MyoD and Pax7 expressing myoblasts was calculated using the following formulae:  
  MyoD positive cells   
 umber of nuclei staining positive for MyoD
Total number of nuclei 
   100   
 
  Pax7  cells   
 umber of nuclei staining positive for Pax7
Total number of nuclei 








3.2.5. Fusion and Differentiation Indices 
Fusion and differentiation indices were analysed as described previously (Micheli et al., 2011). Five 
random fields of view of fused myoblasts stained with myosin heavy chain (MyHC) were captured 
using the Zeiss 710LSM confocal microscope. ImageJ software was utilized to determine myotube 
formation. The fusion and differentiation indices for myotube formation were then calculated using 
the following formulae: 
Differentiation index   
 umber of MyHC positive cells (myocytes and myotubes)
Total number of nuclei
  100 
 
Fusion index   
 umber of nuclei per MyHC positive myotube
Total number of nuclei
  100 
 
3.2.6. Statistics 
All statistical analysis was performed with either a Student’s t-test for parametric data or a Mann-
Whitney-U test for non-parametric data, with values of p<0.05 considered significant. The results 
from each experiment were expressed as Mean ± standard error of the mean (SEM). All 















3.3.1. HGF regulates HSkM myoblast proliferation in a dose-dependent manner  
Proliferation of HSkM myoblasts was assessed using an automated cell counter which allowed 
quantitative determination of cell number. Morphological analysis revealed that following 24 and 
48 h, HGF (10 ng/ml) resulted in a lower cell confluence compared to untreated control and 2 ng/ml 
HGF (Figure 3.1A); this suggested that HSkM proliferation capacity was down-regulated in 
response to 10 ng/ml HGF. Quantitative analysis confirmed this observation. The initial cell 
number plated was 5 x 10
4 
cells. Following 24 h, untreated control cells had doubled their 
population to  1.02 ± 0.055 x 10
5
 cells,  whereas those treated with 10 ng/ml HGF had only 
increased in number to 0.784 ± 0.959 x 10
5
 cells, a significant decrease compared to untreated 
control (p<0.05). Conversely, cells cultured in 2 ng/ml HGF had increased their number to 1.38 ± 
0.039 x 10
5
 cells. This increase was significant compared to untreated control (p<0.05) and 10 
ng/ml HGF (p<0.05).  
A similar trend was observed following 48 h of culture with 2 ng/ml HGF significantly increasing 
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Figure 3.1: Proliferation assay of HSkM myoblasts in response to HGF. Equal numbers of cells (5 x 10
4
) were plated and cultured for 24 h, followed 
by treatment with HGF (0, 2 and 10 ng/ml) for either 24 or 48 h. A) The phase contrast images showing the confluence of HSkM cells in response to HGF 
concentrations. Images were acquired with Motic 2.0 camera at 40 X magnification. Scale bar = 10µm.  B) Proliferation was then analysed via cell counts. 
HGF was observed to affect proliferation in a dose-dependent manner. *p<0.05. All data is mean ± SEM. n=3. 
10 µm 10 µm 10 µm 









3.3.2. HGF stimulates Pax7 expression levels in differentiating HSkM cells. 
Exit of satellite cells from the cell cycle and entry to differentiation requires the down-regulation of 
Pax7 and subsequent increase in MyoD expression (Gal-Levi et al., 1998b). As such, our first step 
was to assess the expression levels of these transcription factors upon treatment of differentiating 
cells with HGF (2 and 10 ng/ml) which would aid our understanding of the role HGF plays in 
myoblast differentiation. 
Morphological assessment revealed maximum Pax7 expression at day 1 and 2 which decreased at 
day 3 and 5 of differentiation. Images of cells following incubation with HGF (10 ng/ml) revealed a 
down-regulation of Pax7 at day 3 compared to untreated control and those incubated with 2 ng/ml. 
By day 5 of differentiation, cells treated with 10 ng/ml HGF were largely devoid of Pax7 (Figure 
3.2).   
The expression patterns of Pax7 in HSkM were quantified and examined for the distribution of the 
Pax7
+ 
subgroup within mononucleated cell populations. On day 1 of differentiation, Pax7 
expression was significantly up-regulated by cells treated with 2 ng/ml HGF (51 ± 1.69%) relative 
to untreated control cells (43.9 ± 2.07%, p<0.05) (Figure 3.3). However, percentage Pax7
+
 cells 
treated 10 ng/ml HGF were similar to untreated control (Figure 3.3). The highest Pax7 expression 
was observed at day 2 post-differentiation in cells treated with 2 ng/ml HGF. Cells treated with 10 
ng/ml HGF revealed a significant decrease in percentage of Pax7
+
 cells (38.2 ± 3.21%) compared to 
untreated control (52.4 ± 3.46%, p<0.05) and 2 ng/ml HGF (53.9 ± 5.14%, p<0.05) (Figure 3.3). 
By day 3, both untreated control cells and those exposed to 10 ng/ml HGF showed a lower 
percentage of Pax7
+
 cells compared to levels observed on day 1 and 2. In response to 2 ng/ml HGF, 
the percentage Pax7
+
 cells were maintained at levels  significantly higher than untreated control and 
10 ng/ml HGF (p<0.05) (Figure 3.3). 
On day 5 of differentiation, a significant decline in percentage of Pax7
+
 cells was identified in 
response to 10 ng/ml HGF (4.7 ± 0.216%) compared to untreated control (12.1 ± 0.665%, p<0.05) 
and 2 ng/ml HGF (27 ± 2.84%, p<0.05). Although percentage Pax7
+
 cells in response to 2 ng/ml 
HGF were decreased by 16% in comparison to day 3, they were still significantly higher than 
untreated control (Figure 3.3). Maintenance of Pax7 expression by cell treated with 2 ng/ml HGF 
suggests delayed differentiation, whilst the decreased expression of Pax7 observed in response to 
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Figure 3.2: Pax7 expression in differentiated HSkM myoblasts in response to HGF. Cells were allowed to differentiate for 1-5 days followed by fixation, 
immunocytochemistry and then analysis using the Zeiss confocal microscope, 40 X magnification. Scale bar = 20µm. Blue indicates the Hoechst nuclear stain and 
red indicates Pax7.  
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Figure 3.3: Percentage  Pax7
+
 cells in response to HGF during differentiation. Cells were allowed to 
differentiate for 1-5 days in the presence or absence of HGF followed by fixation, immunocytochemistry 
at then analysis using the Zeiss confocal microscope. Five random fields of view (from Figure 3.2) were 





3.3.3. HGF increases the number of MyoD expressing HSkM cells 
The expression patterns of MyoD in differentiating human myoblasts following incubation with 
HGF were assessed. Morphological analysis revealed fewer MyoD positive cells in response to 2 
ng/ml HGF at day 1, 2 and 3 of differentiation (Figure 3.4). 
Quantitative analysis of MyoD expression on day 1 demonstrated that cells treated with 2 ng/ml 
HGF revealed 6% and 13% decrease in  MyoD positive cells compared to untreated control 
(p<0.05) and those treated with 10 ng/ml HGF (p<0.05). The percentage MyoD positive cells 
increased significantly in response to 10 ng/ml HGF (39 ± 1.56%) compared to untreated control 
(32.2 ± 3.24%, p<0.05) (Figure 3.5). 
MyoD expression peaked at day 2 across all treatments, however, the greatest increase was 
identified in cells exposed to 10 ng/ml HGF (62.2 ± 1.28%) compared to untreated control (52.4 ± 
0.952%, p<0.05) and those exposed to 2 ng/ml HGF (48.2 ± 2.23%, p<0.05). This increase was 
23% more than the MyoD expression levels that were observed on day 1 (Figure 3.5). 
On day 3 of differentiation, 10 ng/ml HGF resulted in a small, but significant decline in MyoD 
positive cells (33.1 ± 2.15%) compared to untreated control (35.9 ± 0.952%, p<0.05) and 2 ng/ml 
HGF (45 ± 3.13%, p<0.05). This decline was 29% less than the expression that we had observed on 
day 2. The smallest decline in percentage of MyoD positive cells was observed with cell treated 
with 2 ng/ml HGF compared to untreated control (p<0.05) (Figure 3.5). 
On day 5 of differentiation, exposure to 10 ng/ml HGF resulted in  a significant decrease in 
percentage MyoD positive cells (16.2 ± 0.712%) compared to untreated control (22.4 ± 1.18%, 
p<0.05) and 2 ng/ml HGF (25 ± 0.989%, p<0.05). This decrease was 46% less than peak levels 
observed on day 2. In contrast,  cells exposed to 2 ng/ml HGF showed a 23% decrease in MyoD 
positive cells compared to peak levels observed on day 2 (Figure 3.5). 
Overall, exposure of HSkM to 2 ng/ml HGF resulted in increased percentage Pax7
+
 cells and 
decreased percentage MyoD positive cells, suggesting delayed differentiation due to increased 
proliferation. In contrast, incubation of HSkM in 10 ng/ml HGF, revealed a decrease in percentage 
Pax7
+
 cells which was accompanied by increased percentage MyoD positive cells, indicating early 
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Figure 3.4: MyoD expression in differentiating HSkM myoblasts in response to HGF. Cells were allowed to differentiate for 1, 2, 3 and 5 days followed by 
fixation, immunocytochemistry and then analysis using the Zeiss confocal microscope 40 X magnifications. Scale bar = 20µm. Blue indicates the Hoechst nuclear stain; 
green indicates MyoD. 
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Figure 3.5: Percentage MyoD
+
 cells in response to HGF during differentiation. HSkM cells were 
allowed to differentiate for 1-5 days followed by fixation, immunocytochemistry at then analysis using 
the Zeiss confocal microscope. Five random fields of view (from Figure 3.4) were observed for each 












3.3.4. HGF promotes differentiation and myotube formation 
Myoblast differentiation is a crucial step during skeletal muscle regeneration and is characterised 
by a permanent exit from cell cycle and up-regulation of myogenin and myosin heavy chain 
(MyHC). The differentiation of HSkM cells into myotubes was analysed by immunocytochemistry.  
Under brightfield microscopy, we observed that cells cultured in differentiation media containing 
10 ng/ml HGF differentiated more compared to untreated control; whilst a decrease was observed 
in response to 2 ng/ml HGF (Figure 3.6A). This observation was confirmed by confocal 
microscopy of differentiated cells labelled with a mouse monoclonal anti-MyHC antibody. Cells 
incubated with HGF (10 ng/ml) revealed a large number of MyHC positive myotubes which were 
long and striated compared to the untreated control. However, in response to 2 ng/ml HGF, fewer 
myotubes were formed and they demonstrated random alignment compared to untreated control 
(Figure 3.6B).  
HSkM myoblasts first form mononucleated MyHC positive myocytes prior to fusion. We therefore 
quantified a differentiation index, calculated by identifying the number of MyHC positive cells as a 
percentage of the total nuclei per field of view. HGF at a concentration of 10 ng/ml significantly 
increased the differentiation index by 17.6% (61.2 ± 2.27%) compared to control (43.6 ± 4.54%, 
p<0.01). HGF (2 ng/ml) significantly decreased differentiation by 28% compared to 10 ng/ml HGF 
(p<0.01). This decrease was 10.4% significantly less compared to untreated control (p<0.01), at 
(Figure 3.7A).  
We then calculated a fusion index, measured as a percentage nuclei detected in MyHC-labelled 
myotubes (containing two or more nuclei per tube). The fusion index analysis showed a similar 
trend to that observed in differentiation index analysis. A significant increase in the fusion index 
was displayed in response to 10 ng/ml HGF (52.6 ± 1.96%) compared to untreated control (30.8 ± 
2.41%, p<0.01), whereas 2 ng/ml HGF decreased fusion to 24.6 ± 1.23%, compared to untreated 
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Figure 3.6: Myotube formation in differentiated HSkM myotubes treated with HGF. A) Phase contrast images of myotubes formed after day 7 of differentiation 
captured using the Motic 2.0 camera, 10 X maginification. The arrows indicate the myotubes. Scale bar = 10 µm. B) Immunocytochemistry was carried out using MF20, 
an antibody directed against sarcomeric myosin (red) at day 7 of differentiation. Specific antibody labelling was visualized using DyLight 488 secondary antibody (red). 
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Figure 3.7: Differentiation and Fusion indices of HSkM myoblasts (day 7 of differentiation) following incubation with 0, 2 or 10 ng/ml HGF. A) 
Differentiation index of HSkM (day 7 of differentiation). Differentiation index was calculated by identifying the number of cells staining positive for 
MyHC as a percentage of the total nuclei per field of view using ImageJ software. B) The fusion index (i.e. percentage myotubes formed) was analysed for 
each of the HGF treatments using ImageJ software. Fusion index was measured as a percentage of the number of nuclei detected in MyHC-labelled 













Primary cultured human skeletal myoblasts provide additional benefits in research compared to 
immortalised cell lines; primary cultures have been shown to maintain the metabolic characteristics 
of skeletal muscle and thus mimic the actual skeletal muscle physiology more closely (Peault et al., 
2007). However, these cells have finite lifespan and undergo cellular senescence following 
successive divisions (Mamchaoui et al., 2011); (Martin et al., 2009).  
The use of transplantation therapies to treat diseases such as muscular dystrophies or severe muscle 
trauma requires proliferation and myoblast expansion (Peault et al., 2007). Hence investigating and 
understanding the HSkM myoblast proliferative capacity in vitro was of particular interest in this 
study. Findings from animal models suggest that HGF is a major inducer of satellite cell activation 
and proliferation (Morgan and Partridge, 2003, Gal-Levi et al., 1998b). In our study, the 
proliferative capacity of HSkM myoblasts was significantly enhanced by HGF (2 ng/ml), but 
decreased by 10 ng/ml HGF; this suggests a dose-dependent effect on proliferation in response to 
HGF. These findings are similar to the results observed previously in C2C12 myoblasts.  
Myoblast differentiation is essential during skeletal muscle regeneration and is initiated by partial 
or complete restriction of cell proliferation as well as the up-regulation of MyoD, down-regulation 
of the Pax7 transcription factor (Olguin and Pisconti, 2012). In this study, we demonstrate that 
incubation of HSkM in HGF (2 ng/ml) increased the percentage Pax7 expressing cells, but 
decreased MyoD expression when assayed over 3 days in differentiation media. Notably, Pax7 
expression is maintained up to day 5 of differentiation, suggesting a delay in differentiation in these 
cultures.  Contrary to this, treatment of HSkM with HGF (10 ng/ml) decreased the percentage Pax7 
expressing cells, but increased percentage MyoD expressing cells and by day 5 of differentiation, 
the cells were largely devoid of Pax7, suggesting early entry into the differentiation phase. In vivo 
studies on c-Met receptor upon administration of HGF (50 ng/ml) in mice have been shown to 
result in the silencing of MyoD expression (Anastasi et al., 1997). In addition, in vivo c-Met levels 
have also been shown to be regulated during differentiation after direct injection of HGF (6.25 and 
15 ng/ml) into tibialis anterior muscle (Miller et al., 2000). Therefore, the decrease in MyoD 
expression i.e. decreased differentiation in response to HGF (2 ng/ml) could stem from such a 
decrease in receptor levels. So far, however, the pathways involved in the paracrine signalling 





 Human studies by O’Reilly et al. demonstrated that upon activation of satellite cells in human 
skeletal muscle by HGF, the cells begin to up-regulate HGF inhibitors (HAI-1 and HAI-2; see 
chapter 1, section 1.2.3) so that proliferating myoblasts can be driven towards differentiation 
(O'Reilly et al., 2008). We suggest that the increase and decrease in MyoD and Pax7 expression, 
respectively, might be due to increased expression of HGF inhibitors at 10 ng/ml HGF, which assist 
the cells to differentiate faster compared to those treated with 2 ng/ml HGF and untreated control, 
however, this requires further investigation.  
We further investigated the effect of HGF on HSkM myoblast terminal differentiation via 
expression of MyHC. Previous studies have highlighted that cell fusion is accompanied by 
activation of muscle structural genes including MyHC (Airey et al., 1991); (Felsenfeld et al., 1991); 
(Gredinger et al., 1998). Similar studies have shown that the addition of exogenous HGF to satellite 
cells dose-dependently inhibits the expression of MyHC, which is expressed late in muscle 
differentiation (Miller et al., 2000, Bandow et al., 2004). In our study we observed a similar trend 
on the effect of HGF on differentiation.Our data suggest that in HSkM myoblasts, HGF (10 ng/ml) 
enhanced myoblast terminal differentiation and fusion, which was shown by increased MyHC 
expression and percentage fusion levels. However, there was a significant decrease in MyHC 
expression in response to 2 ng/ml HGF, suggesting HGF-induced delay of terminal differentiation 
at this particular dose. Myogenin and MRF4 have been implicated as essential MRFs for terminal 
differentiation. Down-regulation of myogenin during terminal differentiation allows re-entry of 
myoblasts into the cell cycle via down-regulation of MyHC (Mastroyiannopoulos et al., 2012).  
These findings open the possibility of down-regulatory effect of HGF (2 ng/ml) on myogenin 

























Figure 3.8: Schematic representation of the molecular events regulating HSkM myoblast proliferation 
and differentiation in the presence of HGF. Myoblast proliferation was elevated at 2 ng/ml HGF and 
reduced at 10 ng/ml HGF. Under differentiation condition, Pax7 was maintained and less MyoD and MyHC 
was expressed, suggesting delayed differentiation at 2 ng/ml HGF. Opposite effects were observed at 10 
ng/ml HGF; under proliferative condition there was suppressed proliferation accompanied with down-
regulation of Pax7 and up-regulation of MyoD expression. During differentiation, Pax7 was largely down-
regulated and MyHC was greatly expressed suggesting early activation of differentiation in response to 10 
ng/ml HGF. 
 
In summary, our data confirm a dose-dependent effect of HGF on human myoblast proliferation 
and differentiation. Since the onset of differentiation results in partial or complete termination of 
proliferation, HGF (10 ng/ml) supresses proliferation, but increases early entry into differentiation. 
However, a lower HGF concentration (2 ng/ml) results in the opposite effect. Commitment to 
differentiation of myoblasts exposed to HGF (10 ng/ml) is accompanied by elevated expression 
levels of MyoD and down-regulation of Pax7. Our findings therefore highlight that the effect of 
HGF on myogenesis is highly dose-dependent and confirms previous work in C2C12 mouse 





 GENERAL DISCUSSION 
 
Following injury or stress, skeletal muscle is able to regenerate to create new myofibers. 
Regeneration is initiated by satellite cells, quiescent skeletal muscle-specific stem cells, localised 
between the basal lamina and sarcolemma (Dietrich et al., 1999). However, the activity of satellite 
cells during regeneration requires activation of these cells from quiescence, a process facilitated by 
growth factors including HGF (Bischoff, 1994). Upon activation, satellite cells proliferate into 
myoblasts, migrate to site of injury where they differentiate and fuse into myocytes and form 
myotubes to replace the damaged myofibers (Tedesco et al., 2010). HGF is known to play a key 
role not only in satellite cell activation, but also in the regulation of proliferation, migration and 
differentiation; however, the exact effects of HGF on these processes are not well defined in present 
literature. Therefore, in this current study we investigated and compared the effect of HGF on 
mouse versus human myoblast, proliferation, migration and differentiation. A summary of the main 
findings is presented in Table 4.1. 
C2C12 cells represent an immortalized cell line which was originally derived from satellite cells 
from the thigh muscle of female mice. They possess myogenic properties and differentiate first into 
myocytes and after several days in media they form myotubes (Yaffe and Saxel, 1977). Although 
the immortalized C2C12 cell line is a valuable tool for the identification of mechanisms related 
with myogenic processes: activation, proliferation, migration or differentiation; such models do not 
necessarily represent the complexity of skeletal muscle physiology (Peault et al., 2007). In most 
cases, the mutations implemented in these cell lines remain in a mouse context, and there are 
frequently major variances between humans and mice (Mamchaoui et al., 2011). As such, primary 
culture of human cells may be a more physiologically-relevant model and circumvent some of the 










Myogenic process Analysis 
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Table 4.1: Summary of findings from chapters 2 and 3 
Key: ND = Not Done,          
                = increase of myogenic process 
         
               = decrease of myogenic process.  
 





Satellite cell proliferation is an important process in skeletal muscle repair and regeneration, 
however, in vitro the effect of HGF on proliferation is highly dose-dependent (Villena and 
Brandan, 2004, Yamada et al., 2010a). This is supportive to our results which also reflected a 
dose-dependent effect of HGF on myoblast proliferation. Proliferation studies in C2C12 
myoblasts revealed a 4.5 fold increase (relative to number plated) in myoblast number 24 h after 
exposure to exogenous HGF (2 ng/ml). However, when these studies were carried out in HSkM 
myoblasts, a 1.5 fold increase was registered in the presence of HGF (2 ng/ml) after 24 h, and a 
further 3.8 fold increase in cell number was attained after 48 h of culture. Proliferation is known 
to be more responsive to environmental regulation, such as low oxygen culture conditions, in 
mice compared to human cells (Martin et al., 2009). Furthermore, human myoblasts have 
relatively short proliferative lifespan in vivo and their proliferative capacity in vitro is poor 
compared to C2C12 myoblasts (Mamchaoui et al., 2011). This may explain the lower cell 
numbers observed with HSkM myoblasts compared to C2C12 myoblast numbers in the 
presence of exogenous HGF. However, in response to 10 ng/ml HGF, a significant decrease in 
proliferation in both C2C12 and HSkM myoblasts was seen. From these findings, we suggest 
that HGF (10 ng/ml) might have a threshhold dose that supresses proliferation and begins 
promoting other processes e.g. differentiation or migration. 
Leshem et al. demonstrated that HGF receptor coupling to MAPK pathway via the adaptor, 
Grb2, is involved in the stimulation of proliferation and inhibition of myoblast differentiation 
(Leshem et al., 2002). Other studies have revealed cross-talk between the MAPK and PI3K 
pathways downstream of HGF (Yu et al., 2001). Additionally, it has been reported that 
inhibition of PI3K in C2 myoblasts increases cell proliferation, suggesting that activation of this 
pathway might cause a decrease in proliferation (Zeng et al., 2002). We suspect that the MAPK 
pathway contributes to the increase in proliferation in response to 2 ng/ml HGF, while the PI3K 
pathway initiates a decrease in proliferation at higher HGF concentration. Apart from MAPK 
and PI3K, STAT3 signalling pathway has also been implicated in the regulation of myoblast 
proliferation. This pathway is another molecular event that promotes C2C12 myoblast 
proliferation and inhibits differentiation by repressing MyoD expression (Kami and Senba, 
2002); (Sun et al., 2007); (Wang et al., 2008). Given the increase in proliferation observed when 
both C2C12 and HSkM myoblasts were exposed to HGF (2 ng/ml), we propose an implication 
of STAT3 pathway during this effect of HGF. Low affinity binding of HGF to HSPGs 
stimulates activation of MAPK pathways signalling routes that regulate cell proliferation 
(Derksen et al., 2002); this could be the reason for the dose-dependent effects, c-Met versus 





Myoblast differentiation is essential during skeletal muscle repair and is regulated through the 
expression of MRFs including MyoD and transcription factors including Pax7. This process is 
also characterised by partial or complete restriction of cell proliferation i.e. cell cycle exit 
(Olguin and Pisconti, 2012). During differentiation, MyoD expression was stimulated in 
response to 10 ng/ml HGF followed by a down-regulation of Pax7. This is indicative of 
termination of proliferation in the cell population and commitment to differentiation. 
Furthermore, in adult muscle, activation of PI3K is necessary initiation of differentiation 
(Leshem et al., 2002). Therefore, when PI3K activation is above a certain threshold, 
differentiation is stimulated, as observed in our study. It has also been suggested that 
overexpression of an activated form of Ras prevents the differentiation of C2C12 myoblasts 
(Lassar et al., 1989); (Brennan et al., 1990). A separate study suggested that binding of c-Met to 
Grb2 supresses p38 activation, hence contributing to the inhibitory effect of HGF on skeletal 
muscle differentiation (Leshem et al., 2002).  As a result, further work to elucidate the activity 
of the MAPK and PI3K pathways in response to HGF would be prudent.  
HGF has been reported to regulate the differentiation of the chicken skeletal muscle satellite 
cells and C2 myogenic cell line by controlling the expression levels of MyoD (Anastasi, 1997); 
(Gal-Levi et al., 1998b); (Leshem et al., 2000). Exposure of C2 myoblasts to exogenous HGF 
(10 ng/ml) demonstrated suppression of Pax7 and induction of MyoD, activities that were 
shown to be  essential for myoblasts to complete the cell cycle and enter the differentiation 
process (Yamane et al., 2004); (Gill et al., 2010). These results are consistent with our findings; 
exogenous HGF (10 ng/ml) stimulated both C2C12 and HSkM myoblast to enter the 
differentiation process by supressing Pax7 expression. Moreover, work by Yoshida et al., 
showed that down-regulation of MyoD induces self-renewal and quiescence of C2C12 
myoblasts (Yoshida et al., 1998), hence we propose that the down-regulation of MyoD 
expression at 2 ng/ml indicates that HGF  delays differentiation and promotes proliferation. In 
C2C12 myoblasts, MyoD expression was largely down regulated by day 3 of differentiation but 
in HSkM myoblasts, expression of this protein was down regulated by day 5 of culture. 
Interestingly, both C2C12 and HSkM myoblasts revealed a peak in MyoD expression by day 2 
of differentiation, followed by a decrease at day 3. As early as day 3, C2C12 myoblasts were 
showing alignment indicative of entry into terminal differentiation. This was confirmed at day 5 
when these cells formed myotubes. In contrast, the HSkM myoblasts showed alignment by day 
5 and fusion and myotube formation was only observed at day 7 of differentiation. In all these 
observations, we noted that the effect of HGF on differentiation was highly dose-dependent. 
Since, MyoD expression was elevated at 10 ng/ml HGF compared to 2 ng/ml HGF, we 
expected increased MyHC expression at 10 ng/ml compared to 2 ng/ml HGF, as MyoD has 




alpha-actin (Burattini et al., 2004). We observed that higher doses of HGF (10 ng/ml) resulted 
in increased MyHC expression associated with a 48% fusion index in C2C12 myoblasts and a 
52.6% was observed in HSkM myoblasts. A lower HGF concentration (2 ng/ml) resulted in 
lower MyHC expression associated with a 29.4% fusion index in C2C12 myoblasts and 24.6% 
in HSkM myoblasts. These data highlight that although HGF differentially affects myoblast 
differentiation in a dose-dependent manner, the absolute effects are essentially the same in both  
HSkM and C2C12 myoblasts. 
Analysis of the percentage wound closure indicated that HGF (10 ng/ml) while decreasing 
proliferation, stimulated migration. The lower HGF dose (2 ng/ml) that increased proliferation, 
on the other hand, resulted in reduced wound closure. Vinculin is a ubiquitously expressed actin 
filament binding protein that localizes in focal adhesions and is known to be actively involved 
in myoblast migration (Le Clainche and Carlier, 2008). Vinculin expression levels have been 
shown to be higher in migrating cells, as it is mainly involved in the regulation of focal 
adhesions of migrating cells (Moon et al., 2004). Cells treated with 10 ng/ml HGF revealed 
higher vinculin expression levels which correlated with an increased percentage wound closure. 
Our results therefore indicate that HGF affects vinculin expression in migrating C2C12 
myoblasts in a dose-dependent manner. For future studies, the examination of migration of 
primary cultured human myoblasts in the presence of HGF is essential to confirm C2C12 
results. The ability of HGF to either negatively or positively alter migratory capabilities via 
vinculin expression of satellite cells is supportive of its function in skeletal muscle repair 
(Bischoff, 1997, Yamada et al., 2010b). 
Taken together, our results demonstrate the central role that HGF plays during all the myogenic 
processes involved in the stages of skeletal muscle regeneration in both mouse C2C12 myoblast 
lines and primary cultured human myoblasts. HGF stimulates myoblast expansion and growth 
by means of mitogenic activities. Although the effects of HGF are highly dose-dependent, the 
extent of the effects on proliferation and differentiation are differential and dependent on the 
cell type. In an injury scenario, our data suggests that at lower HGF concentrations (2 ng/ml); 
proliferation is stimulated to increase cell population to initiate beginning of repair. Increasing 
HGF concentration (10 ng/ml) (later during injury) accelerates the transition of myoblasts from 
proliferation to differentiation to promote alignment, fusion and repair. We therefore conclude 
that the modulation of myogenic processes (proliferation and differentiation) by HGF indicate 
the importance of this cytokine in skeletal muscle regeneration and is a potential drug target for 
muscle disease. We hope that further studies in primary cultured human myoblasts may lead to 


























Figure A: Blast sequence alignment of Human and Mouse (Mus musculus) HGF retrieved from 
National Centre for Biotechnology (NCBI) Protein database using the Basic Local Alignment 
Search Tool (BLAST) on 31/06/13. The results show 91% amino acid similarities between mice and 
































 CELL CULTURE REAGENTS 
 
C2C12 Myoblast Growth Media (10% v/v FCS): A solution of 430 ml Dulbecco’s Modified 
Eagle Serum (DMEM) (Thermo Scientific Laboratories, USA, cat.SH30243.01), 10 ml L-
glutamine (2% v/v) (Lonza, USA, cat.BE17-605E), 10 ml PenStrep (2% v/v) (Lonza, USA, 
cat.DE17-602E), and 50 ml fetal calf serum (10% v/v) (Biowest, USA, cat.S181H-500) was 




C2C12 Myoblast Differentiation Media (2 % v/v HS): A solution of 475 ml DMEM (Thermo 
Scientific Laboratories, USA, cat.SH30243.01), 10 ml L-glutamine (2 % v/v) (Lonza, USA, 
cat.BE17-605E), 10 ml PenStrep (2% v/v) (Lonza, USA, cat.DE17-602E) and 5 ml horse serum 
(HS, 1% v/v) (Biowest, USA, cat.S090H-100) was made up and filter sterilized. The media was 
aliquoted into 50 ml falcon tubes and stored at 4
o
C. 
Skeletal Muscle Cell Medium BulletKit® (Lonza, USA, cat.CC3161): The bulletkit is bought 
already made-up by the manufacturer. It is composed of 500 ml of Skeletal Muscle Cell Basal 
Medium and the following growth supplements: 0.5 ml hEGF, 5 ml insulin, 5 ml Fetuin, 0.5 ml 
Dexamethasone, 0.5 ml GA-1000 and 5 ml BSA. The media was aliquoted into 50 ml falcon 
tubes and stored at 4
o
C. 
Human Myoblast Growth Media (10% v/v FCS):  A solution of 152 ml HAMS-F10 (Life 
Technologies, South Africa, cat.31550-015), 4 ml L-glutamine (2% v/v) (Lonza, USA, 
cat.BE17-605E), 4 ml PenStrep (2% v/v) (Lonza, USA, cat.DE17-602E), 2.5 ng/ml FGF 
(Promega, USA, cat.G507A) and 40 ml fetal calf serum (20 % v/v) (Biowest, USA, cat.S181H-




Human Myoblast Differentiation Media (2 % HS): A solution of 188 ml HAMS-F10 (Life 
Technologies, South Africa, cat.31550-015), 4 ml L-glutamine (2% v/v) (Lonza, USA, 
cat.BE17-605E), 4 ml PenStrep (2% v/v) (Lonza, USA, cat.DE17-602E) and 4 ml horse serum 
(HS, 2% v/v) (Biowest, USA, cat.S090H-100) was made up and filter sterilized. The media was 
aliquoted into 50 ml falcon tubes and stored at 4
o
C. 
Hepatocyte Growth Factor (HGF) preparation:  Human HGF (PeproTech, USA; cat.100-39) 
was made up to a stock concentration of 10 µg/ml in sterile PBS and was stored in 50 µl 
aliquots at -20
o




differentiation media to final concentrations of 2, 10 and 50 ng/ml and was used to assess 
proliferation, migration and differentiation. 
Sterile Phosphate buffered saline (PBS; pH 7.2): 16 g NaCl, 0.4 g KCl, 2.3 g Na2HPO4 and 0.4 
g KH2PO4 were dissolved in 1.6 liters distilled water and stirred with a magnetic stirrer until 
dissolved. The pH was adjusted to pH 7.2 with HCl. Separately, 0.264 g CaCl2 was dissolved in 
200 ml distilled water and 0.2 g MgCl2.6H2O was dissolved in 200 ml distilled water. All three 
solutions were autoclaved and then added together once they had cooled to make up sterile PBS 
for cell culture. 
Sterile Trypsin: Since C2C12 cells are adherent cells, trypsin (Highveld, USA, cat.CN3796) 
was used to lift them up during experiments. The trypsin contained 0.125% Trypsin, 0.1% 




 free PBS. The trypsin was stored in 50 ml aliquots at 4
o
C and 
was always warmed in a 37
o




















CRYOPRESERVATION (LIQUID NITROGEN STORAGE), THAWING, PASSAGING, 
AND DIFFERENTIATION 
 
Cells were stored in cryotubes (Nunc, USA, cat.65232) containing growth media supplemented 
with 10% v/v DMSO in 1 ml aliquots of approximately 1 x 10
6
 cell in liquid nitrogen (-196
o
C). 
For experimentation, cells were thawed for one minute in a water bath at 37
o
C, and then 
instantly transferred to a T25 flask tissue culture flask (Nunc, USA, cat.156367) containing 4 
ml of warm growth media. 
When cells had reached ~70% confluence, they were split 1:4 and moved to a different T75 
flask. To passage, cell media within a T75  tissue culture flask (Nest, USA, cat.0926B) was 
discarded and cells were washed with warm sterile PBS. After discarding the PBS, 2 ml of 
trypsin was then added to the flask and incubated at 37
o
C for 3-5 min. Equal volume of growth 
media was added to cells to neutralize the trypsin. The cells were then split into new T75 flasks 
containing warm growth media and cultured for future use, or counted and plated out for 
experiments. 
Differentiation was performed in 24-well tissue culture plates (Cell Star, USA, cat.662160) on 
12 mm round coverslips (Lasec, USA, cat.0111520). Initially, the cells were cultured in growth 
media, until they were 80% confluent. The growth media was then replaced with differentiation 
media.  Cells were incubated at 37
o
C in a humidified atmosphere at 5% CO2
 
for either 1-5 days 













DETERMINATION OF CELL CULTURE CONTAMINATION 
 
Culture contaminants were determined either by confocal or brightfield microscopy as 
described previously (Stacey, 2011). Briefly, for confocal microscopy, 1x 10
4
 cells were plated 
out in 24 well plates on coverslips and incubated for 24 h, thereafter they were fixed with 4% 
paraformaldehyde for 15 min and stained with Hoechst (1: 2000) for 5 min. After several 
washes with PBS, coverslips were mounted with 4 µl Moviol onto microscope slides and 
viewed with the Zeiss confocal microscope. The presence of blue string-like structures around 
the nuclei indicated the presence of mycoplasma. For brightfield microscopy, 5 x 10
4
 cells were 
plated out in T25 tissue culture flasks and incubated for 24 h; pictures were then taken with the 
Motic 3 megapixel camera at 40 X magnification. Black, rod-like shaped motile particles 
indicated bacteria contamination, which was associated with suppressed cell growth and 
increased cell death. Budding, shiny structures within cell cultures (visible for a few hours, 
however, after several hours the culture media became turbid) indicated the presence yeast 














Figure D: Confocal and bright-field Images of different types of contamination. i) Confocal images of 
non-contaminated C2C12 cells. ii) Phase contrast images non-contaminated C2C12 cells. iii) C2C12 cell 
nuclei and mycoplasma stained brightly under confocal microscopy allowing clean culture (i) to be easily 
distinguished from infected culture (iii). iv) Budding yeast cells within cell culture indicating the presence of 















y = 1E-05x 



























 Cell number 
APPENDIX E: 
CRYSTAL VIOLET STANDARD CURVE  
Reagents 
0.2% Crystal violet dye:  0.2 g of crystal violet powder (Sigma, Germany, cat.C-3886) was 
dissolved in 100 ml methanol. The solution was stored in a plastic bottle at room temperature. 
Method 
Cells were plated out at initial densities of 10 000, 20 000, 40 000 and 80 000 cells in six well 
plates containing growth media and incubated at 37
o
C, 5% CO2 for 24 h. Media was removed 
and cells were stained with crystal violet dye for 10 min. The wells were then washed with 
distilled water and 1% sodium dodecyl sulphate (SDS) was then added to solubilize the cells. 
100 µl of cell solutions were then transferred to a 96 well ELISA plate (this was done in 
triplicate). Using FluoStar Optima microplate reader machine (BMG, Labtech, USA), 
absorbance readings were obtained and a standard curve generated. The linear equation 
generated from the curve was then used to calculate the cell numbers during subsequent 









Figure E: Crystal violet assay standard curve. The graph illustrates a linear relationship between 








ANTIBODY OPTIMIZATION FOR IMMUNOCYTOCHEMISTRY 
 
To determine the best antibody concentrations to use during subsequent immunocytochemistry 
experiments, a series of antibody dilutions were used. Initially, ~3 x 10
4 
 cells were plated out 
on coverslips in 24 well tissue culture plates (in duplicates) and cultured for 24 h. Media was 
removed, cells were washed with PBS then fixed for 15 min with 4% paraformaldehyde. This 
was followed by several washes of the cells with PBS then blocking with 5% donkey serum for 
30 min and incubation with serially-diluted antibody solutions overnight at 4
o
C. Serially diluted 
secondary antibody solutions were then added after several washes of the cells with PBS. 
Hoechst was then added at a final concentration of 1:2000 and several washes were carried out. 
Finally coverslips were mounted on microscope slides with Moviol then viewed with the Zeiss 
confocal microscope. The dilution range that revealed moderate brightness was then applied  



























Figure F: Antibody optimization for immunocytochemistry: hypothetical layout of primary and 



















OPTIMIZATION OF ANTIBODIES FOR WESTERN BLOTS: DOT BLOTS  
Reagents 
Immuno Star™  estern C™ Kit: The kit (Biorad, USA, cat.170-5070) contained 
Lumino/Ehancer solution and peroxidase solution, which was made up in a 1:1 ratio prior to 
immediate use. 
Method 
 Dot blots were performed to determine the best antibody concentrations to use during 
subsequent western blot experiments. On a small piece of nitrocellulose, small circles were 
drawn in pencil and 1µl of cell lysates was placed in the circle and allowed to air dry. Non-fat 
milk (5% (m/v)) made up in Tween-Tris Buffer Saline (TTBS) (Appendix L) was then used to 
block for 3 h. (NB: gloves should be worn at all times when handling protein lysates and 
nitrocellulose). Different ranges of primary antibodies were made up in TTBS in serial dilutions 
and added for 2 h. The papers were washed several times with TTBS on a rocker. Different 
ranges of the secondary antibody also made up in TTBS were the applied for 1 h and several 
washes were done using TTBS. (NB: Each primary and secondary antibody has its own 
recommended dilution determined from literature and data sheets (Appendix H)). Immuno 
Star™ estern C™ Kit was added to the nitrocellulose paper which had been placed between 
two pieces of transparent film. Enhanced Chemiluminescence was used for development of dots 
on light film (Kodak Biomax Light film; Sigma, Germany) in the dark room with no white 
light. The light film was exposed to the nitrocellulose paper for 30 sec -10 min depending on 
primary antibody. After exposure, the film was first placed in developer ((1:3 dilution in water) 
Structirix G128, Agfa, USA) until dots were formed, then secondly in fixative solution ((1:4 
dilution in water) G333c Rapid fixer, Agfa, USA), finally in water. The dilution range that 
showed maximal binding of both primary and secondary antibodies without non-specific 




     
   
   












Figure G: Antibody optimization for western blot: hypothetical layout of primary and secondary 







ANTIBODY DILUTIONS AND STAINS FOR WESTERN BLOT ANALYSIS AND 
CONFOCAL MICROSCOPY 
Table H.1: Primary antibody dilutions used for western blot analysis and 
immunocytochemistry 

































Bank, USA, MF29 
α-tubulin Mouse 
monoclonal 
~52-55 ECL 1/50 Santa Cruz, USA, sc-
5286 
 
Table H.2: Secondary antibody dilutions used for western blot analysis and 
immunocytochemistry (ICC) as well as immunohistochemical stains 
Antibody Application Dilution 
factor 
Company 




1/8000 Dako, USA, P-0260 




1/4000 Dako, USA, P-0448 
Hoechst 33342 Nuclear 
Stain 
1/2000 Sigma, Germany, B2261 
Phalloidin-TRITC Cytoskeletal 
stain 
1/16 000 Sigma, Germany, P1951 
DyLight 488-conjugated AffiniPure 
donkey anti-rabbit lgG 
ICC 1/1000 Jackson ImmunoResearch, 
USA, cat.CN-711-485-152 
DyLight 488 and 594-conjugated 
AffiniPure donkey anti-mouse lgG 
ICC 1/1000 Jackson ImmunoResearch, 
USA, cat.CN-715-485-151 
DyLight 594-conjugated AffiniPure 
donkey anti-mouse lgG 
ICC 1/1000 Jackson ImmunoResearch, 
USA, cat.CN-715-515-151 
DyLight 549-conjugated AffiniPure 
donkey anti-goat lgG 








CELL LYSATE PREPARATION  
Reagents 
RIPA Buffer (pH 8): RIPA buffer (Sigma, Germany, cat.R0278) consists of; 50 mM Tris-HCl 
with 150 mM NaCl, 1% Igepa CA-630 (NP-40), 0.5% sodium deoxycholate and 0.1% sodium 
dodecyl sulfate (SDS). The buffer was stored at 4
o
C. 
Protease Inhibitor Cocktail (PIC): The PIC (Sigma, Germany, cat.P8340) comprises of the 
following enzymes; pepstain A, leupeptin hemisulfate, AEBSF- [4-(2-
Aminoethyl)benzenesufonyl fluoride hydrochloride], aprotinin, bestatin hydrochloride and E-
64-[N-(trans-Epoxysuccinyl)-L-leucine 4- guanidinobutylamide]. PIC was aliquoted into 20 µl 




Cells were harvested after trypsinizing for 3-5 min and centrifuged at 12 000g for 5 min on a 
bench top centrifuge (MRC, Polychem Supplies, USA). The supernatant was discarded and then 
the cell pellet was resuspended in 100 µl RIPA and 1 µl of PIC and lysed while incubated on 
ice for 1 h. The cell suspensions were then sonicated using Ultrasonic cleaner (Shalam 
Laboratory Suppliers) and the protein concentration determined using the equation obtained 
from Bradford Protein Assay (Appendix J). The suspensions were aliquoted into small volumes 















y = 0.028x + 0.0059 



























BSA concentration (µg) 
APPENDIX J: 
BRADFORD PROTEIN ASSAY  
Reagents 
Bradford Reagent: The reagent (Sigma, USA, cat.B 6916) contains Brilliant blue G in 
phosphoric acid and methanol. The reagent was stored at 4
o
C. A standard curve was created 
using bovine serum albumin (BSA) (Roche Diagnostic, USA, cat.70117254) stock solution (1 
mg/ml). 
Method 
A solution of PBS, 1 mg/ml Bovine Serum Albumin stock and Bradford reagent (Sigma-
Aldrich, USA; cat.081M4362) was made up as follows: 0, 5, 10, 15, 20, 25, 30 µl BSA stock 
was aliquoted into 1 ml plastic micro-cuvettes (Lasec, cat.PLPS112117), PBS was added in 
decreasing amounts of 100, 95, 85, 80, 75, 70 µl and a constant volume of 900 µl Bradford 
reagent was added (this was done in replicates of five to get an accurate assessment of protein 
concentrations). The absorbance values of the solutions were measured at 595 nm and the 
average absorbance calculated and used to generate the standard curve (Figure J). Thereafter, 5 
µl of cell lysate was added to 95 µl PBS buffer and 900 µl Bradford reagent. Absorbance was 
read at 595 nm. Protein concentrations were calculated using the linear equation generated from 










Figure J: Bradford protein assay standard curve. The graph shows a linear relationship between 
absorbance of BSA protein solution at 595 nm and BSA concentration. The graph shows the standard 





SODIUM DODECYL SULFATE POLYACRYLAMIDE GEL (SDS-PAGE) 
Reagents 
Acrylamide/Bis-acrylamide monomer stock solution: 73 g acrylamide (30% m/v) and 2 g bis-
acrylamide were dissolved in 250 ml distilled water. The solution was filter through Whatman 
No 1 filter paper and stored at 4
o
C in a brown glass bottle. 
4 x running gel buffer (1.5M Tris-HCl, pH 8.8): 72.72 g Tris was dissolved in 400 ml distilled 
water. The pH was adjusted to pH 8.8 with HCl. The solution was stored at 4
o
C. 
4 x stacking gel buffer (500 mM Tris-HCl, pH 6.8): 3 g Tris was dissolved in 50 ml distilled 
water. The pH was adjusted to pH 6.8 with HCl. This solution pH was checked every time 
before running the gel and stored at 4
o
C. 
SDS stock solution (10% w/v SDS): 5 g SDS was dissolved in 50 ml distilled water. The 
solution was stored in a glass bottle at room temperature. 
Ammonium persulfate initiator solution: 0.1 g ammonium persulfate was dissolved in 1 ml 
distilled water. This initiator was made up fresh every time before use. 
2 x Reducing sample treatment buffer (125 mM Tris-HCl, pH 6.8): 2.5 ml of 4 x stacking gel 
buffer, 4 ml SDS stock solution, 2 ml glycerol and 1 ml 2-mercaptoethanol were made up to 10 
ml with distilled water and adjusted to pH 6.8. This solution was stored in a plastic container at 
room temperature for not more than 2 weeks.   
Electrode (tank) buffer (250 mM Tris-HCl, pH 8.3): 0.75 g Tris, 3.6 g glycine and 2.5 ml SDS 
stock solution were made up to 250 ml distilled water and titrated to pH 8.3. The solution was 
stored in a plastic container at 4
o
C. 
Coomassie R-250 stain: 1.25 g Coomassie brilliant blue R-250, 225 ml methanol, 50 ml 
glycerol, 200 ml distilled water were mixed together and made up to 500 ml with distilled 
water. The solution was stored in a plastic container at room temperature. 
Destain solution 1 (50% (v/v) methanol, 10% (v/v) acetic acid): 500 ml methanol, 100 ml acetic 
acid were measured and made up to 1 litre with distilled water. The solution was stored in a 




Destain solution 2 (70% (v/v) methanol, 5% (v/v) acetic acid): 50 ml methanol, 70 ml acetic 
acid were measured and made up to 1 litre with distilled water. The solution was stored in a 
plastic container at room temperature. 
Coomassie Binding Blue  G-250 stain dye: 0.2 g Coomassie G-250, 2.4 ml phosphoric acid, 50 
g aluminium sulfate, 100 ml ethanol (100%) and 876 ml distilled water were combined, stirred 
and stored in a plastic container at room temperature. (NB: This stain does not require 
destaining). 
Method 
Laemmli system was used for SDS-PAGE (Laemmli, 1970) with several amendments. The Bio-
Rad electrophoresis unit (Bio-Rad Mini-PROTEAN 3 Cell) was used for running all gels. 
Stacking gel (12.5%) was prepared according to Table K and the gels were cast into space 
between two glass plates to a depth of ~3 cm from the top of the glass plate. The gels were 
immediately overlayed with distilled water to allow for even polymerization. Once the gels 
were set (evidenced by the appearance of the interface between gel solution and water), the 
water was removed. Stacking gel solution was then poured in, up to the top of the glass plate 
and a 10 well comb inserted to form the sample application wells. Once the gels had set, the 
wells were rinsed with distilled water. The Bradford protein assay was used to determine 
protein (30 ug) concentration (Appendix J); each sample was added to an equal volume of 
reducing treatment buffer. Samples were immersed in boiling water for 2-3 min (to denature the 
proteins) and allowed to cool on ice. (NB: All protein lysates must be kept on ice to avoid 
protein degradation). Tank buffer was poured into the inner and outer electrode compartments, 
samples and 3 µl PeqGold protein marker V (Peqlab, USA, cat.27-2210) were then loaded on 
the gels. The gel unit was connected to a power pack and gels were then run at room 
temperature at a constant current of 18 mA/gel (for ~ 1 h 30 min) until the bromophenol blue 
tracker dye was 0.5 cm from the bottom of the gel unit. The gels were removed from the glass 
plates and loaded for western blot analysis. After western blot, the gels were stained with 
Coomassie binding blue G-250 to determine total protein transfer. 
Reagent 12.5% running gel Stacking gel 
Acrylamide/Bis-acrylamide 
monomer stock solution 
6.25 ml 940 µl 
4 x running gel buffer 3.75 ml - 
4 x stacking gel buffer - 1.75 ml 
SDS stock solution 150 µl 70 µl 
Ammonium persulfate initiator 
solution 
75 µl 35 µl 
distilled water 4.75 ml 4.3 ml 
TEMED 7.5 µl 15 µl 








Blotting Buffer: 30.325 g Tris and 72 g Glycine were dissolved in 4.5 litres distilled water, 
followed by addition of 1 litre methanol. The solution was made up to 5 litres with distilled 




Tween-Tris Buffer Saline (TTBS; 20 mM Tris, 150 mM NaCl, 0.05% Tween 20) pH 7.5: 8 g 
NaCl, 0.2 g KCl, 3 g Tris base were weighed out and dissolved in 800 ml distilled water. The 
pH was titrated to pH 7.5 with HCl and volume was bought to 1 litre with distilled water. 0.5 ml 
Tween (Sigma, Germany, cat.P1379) was added to the solution and the buffer was stored in a 
plastic container at 4
o
C. 
Ponceau S. stain: 0.1 g Ponceau S (Fluka, USA, cat.81460) was dissolved in 1 ml acetic acid 
(100%) and made up to final volume of 100 ml distilled water. The solution was adjusted to pH 




After running the SDS-PAGE gel (Appendix K), western blot analysis was performed. The gel 
was placed within a blotting sandwich made up as follows: 1 x sponge, 2 x blotting paper, 
nitrocellulose membrane (Life Sciences, South Africa, cat.P/N 66485), gel, 2 x blotting paper, 
and sponge. This was carried out in blotting buffer, and air bubbles were removed. The 
sandwich was transferred into a western blot cassette and placed into the western blot apparatus 
(Cleaver Scientific Ltd, USA) containing blotting buffer. Since proteins are negatively charged, 
the gel was placed on the positive terminal and the nitrocellulose on the positive terminal of the 
apparatus. Protein transfer was performed in the fridge (4
o
C) at 200 mA for 16 h. 
The nitrocellulose was then placed in Ponceau S stain for detection of proteins. The 
nitrocellulose was washed with distilled water and an image of the membrane was captured 
using a Versa Doc imaging system (Biorad, USA). The gel was placed in Coomassie G-250 
stain overnight, to determine total transfer. The nitrocellulose membrane was blocked with 5% 
(m/v) non-fat milk powder made up in TTBS for 2 h on a shaker. Thereafter, the nitrocellulose 
was cut at molecular weights of the antibodies that were going to be probed for and placed in 
the appropriate antibody dilution made up in TTBS overnight at 4
o
C. This was followed with a 




up in TTBS for 1 h on shaker with vigorous agitation. The nitrocellulose was washed (6 x 8 
min) in TTBS.  
Immuno Star™  estern C™ Kit (Appendix G) was added to the nitrocellulose membrane 
which had been placed between two pieces of transparent film. The film was first cleaned with 
70% ethanol and dried prior to use. Enhanced Chemiluminescence (ECL) technique was 
applied for the development of bands on light film (Kodak Biomax Light film; Sigma, USA) in 
the dark room with no white light. The light film was exposed to the nitrocellulose paper for 30 
sec -10 min depending on primary antibody. After exposure, the film was first placed in 
developer ((1:3 dilution in water) Structirix G128, Agfa, USA) until dots were formed were 
performed, then secondly in fixative solution ((1:4 dilution in water) G333c Rapid fixer, Agfa, 
USA), finally in water. The film was allowed to dry and an image of it was taken using 
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